<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">78163</article-id><article-id pub-id-type="doi">10.7554/eLife.78163</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-272384"><name><surname>Cai</surname><given-names>Wesley L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3871-5509</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-272383"><name><surname>Chen</surname><given-names>Jocelyn Fang-Yi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7281-8686</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-272385"><name><surname>Chen</surname><given-names>Huacui</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-272386"><name><surname>Wingrove</surname><given-names>Emily</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-272387"><name><surname>Kurley</surname><given-names>Sarah J</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-273188"><name><surname>Chan</surname><given-names>Lok Hei</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-273189"><name><surname>Zhang</surname><given-names>Meiling</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273190"><name><surname>Arnal-Estape</surname><given-names>Anna</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0490-7040</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273191"><name><surname>Zhao</surname><given-names>Minghui</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8928-9258</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273192"><name><surname>Balabaki</surname><given-names>Amer</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1509-886X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-209844"><name><surname>Li</surname><given-names>Wenxue</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-273193"><name><surname>Yu</surname><given-names>Xufen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7794-7890</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288320"><name><surname>Krop</surname><given-names>Ethan D</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-217941"><name><surname>Dou</surname><given-names>Yali</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-209843"><name><surname>Liu</surname><given-names>Yansheng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2626-3912</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-130905"><name><surname>Jin</surname><given-names>Jian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2387-3862</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-3015"><name><surname>Westbrook</surname><given-names>Thomas F</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-6306"><name><surname>Nguyen</surname><given-names>Don X</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0324-5604</contrib-id><email>don.nguyen@yale.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-38365"><name><surname>Yan</surname><given-names>Qin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4077-453X</contrib-id><email>qin.yan@yale.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04ehecz88</institution-id><institution>Hillman Cancer Center, University of Pittsburgh Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Department of Pathology, Yale University</institution></institution-wrap><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Department of Biochemistry and Molecular Biology, Baylor College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03j7sze86</institution-id><institution>Yale Cancer Center, Yale School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale Cancer Biology Institute, Department of Pharmacology, Yale University</institution></institution-wrap><addr-line><named-content content-type="city">West Haven</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Mount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/008zs3103</institution-id><institution>Department of Biosciences, Rice University,</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Department of Pathology, University of Michigan, Ann Arbor</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03taz7m60</institution-id><institution>Department of Medicine, Department of Biochemistry and Molecular Medicine, University of Southern California</institution></institution-wrap><addr-line><named-content content-type="city">Los Angeles</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution>Yale Stem Cell Center, Yale School of Medicine</institution><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution>Department of Internal Medicine (Section of Medical Oncology), Yale School of Medicine,</institution><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff13"><label>13</label><institution>Yale Center for Immuno-Oncology, Yale School of Medicine</institution><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zwart</surname><given-names>Wilbert</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xqtf034</institution-id><institution>Netherlands Cancer Institute</institution></institution-wrap><country>Netherlands</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>White</surname><given-names>Richard M</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02yrq0923</institution-id><institution>Memorial Sloan Kettering Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>31</day><month>08</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e78163</elocation-id><history><date date-type="received" iso-8601-date="2022-02-25"><day>25</day><month>02</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-08-24"><day>24</day><month>08</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-03-30"><day>30</day><month>03</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.03.30.486357"/></event></pub-history><permissions><copyright-statement>© 2022, Cai, Chen et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Cai, Chen et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-78163-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-78163-figures-v2.pdf"/><abstract><p>Metastatic breast cancer remains a major cause of cancer-related deaths in women, and there are few effective therapies against this advanced disease. Emerging evidence suggests that key steps of tumor progression and metastasis are controlled by reversible epigenetic mechanisms. Using an in vivo genetic screen, we identified WDR5 as an actionable epigenetic regulator that is required for metastatic progression in models of triple-negative breast cancer. We found that knockdown of WDR5 in breast cancer cells independently impaired their tumorigenic as well as metastatic capabilities. Mechanistically, WDR5 promotes cell growth by increasing ribosomal gene expression and translation efficiency in a KMT2-independent manner. Consistently, pharmacological inhibition or degradation of WDR5 impedes cellular translation rate and the clonogenic ability of breast cancer cells. Furthermore, a combination of WDR5 targeting with mTOR inhibitors leads to potent suppression of translation and proliferation of breast cancer cells. These results reveal novel therapeutic strategies to treat metastatic breast cancer.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>breast cancer</kwd><kwd>cancer metastasis</kwd><kwd>translation regulation</kwd><kwd>WDR5</kwd><kwd>KMT2</kwd><kwd>MLL</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>Graduate Research FellowshipDGE-1122492</award-id><principal-award-recipient><name><surname>Cai</surname><given-names>Wesley L</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>F31CA243295</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Jocelyn Fang-Yi</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000090</institution-id><institution>Congressionally Directed Medical Research Programs</institution></institution-wrap></funding-source><award-id>W81XWH-15-1-0117 and W81XWH-21-1-0411</award-id><principal-award-recipient><name><surname>Yan</surname><given-names>Qin</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01CA237586</award-id><principal-award-recipient><name><surname>Yan</surname><given-names>Qin</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01CA166376</award-id><principal-award-recipient><name><surname>Nguyen</surname><given-names>Don X</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30CA016359</award-id><principal-award-recipient><name><surname>Nguyen</surname><given-names>Don X</given-names></name><name><surname>Yan</surname><given-names>Qin</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010900</institution-id><institution>Yale Cancer Center</institution></institution-wrap></funding-source><award-id>Class of '61 Cancer Research Award</award-id><principal-award-recipient><name><surname>Nguyen</surname><given-names>Don X</given-names></name><name><surname>Yan</surname><given-names>Qin</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1S10OD025132 and 1S10OD028504</award-id><principal-award-recipient><name><surname>Jin</surname><given-names>Jian</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The chromatin regulator WDR5 is a regulator of translation, and small molecule inhibitors or degraders of WDR5 can be used to treat triple-negative breast cancer.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>In the United States, metastatic breast cancer is the second leading cause of cancer-related death among women (<xref ref-type="bibr" rid="bib30">Harbeck et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Torre et al., 2017</xref>). In particular, triple-negative breast cancer (TNBC) has the worst prognosis among all breast cancer subtypes, largely owing to its high metastatic proclivity to the lungs and other sites and because there are few effective treatments against this disease once it has metastasized (<xref ref-type="bibr" rid="bib3">Al-Mahmood et al., 2018</xref>). Recently developed targeted therapies for TNBC, including poly (ADP-ribose) polymerase inhibitors or immune checkpoint inhibitors, are effective in patients whose tumors express BRCA1/2 mutations or high programmed death-ligand 1, respectively (<xref ref-type="bibr" rid="bib25">Gonzalez-Angulo et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Lyons and Traina, 2019</xref>). However, these patients account for only 9.3–15.4% of TNBC cases (<xref ref-type="bibr" rid="bib6">Armstrong et al., 2019</xref>), and new treatment strategies are urgently needed.</p><p>Emerging evidence suggests that tumor growth is modulated by reversible epigenetic mechanisms (<xref ref-type="bibr" rid="bib11">Blair and Yan, 2012</xref>; <xref ref-type="bibr" rid="bib16">Cao et al., 2014</xref>; <xref ref-type="bibr" rid="bib15">Cao and Yan, 2013</xref>; <xref ref-type="bibr" rid="bib19">Chen and Yan, 2021</xref>). In primary human breast cancers, we and others recently identified distinct chromatin states, which distinguish established molecular subtypes and correlate with metastatic relapse and poor clinical outcome (<xref ref-type="bibr" rid="bib14">Cai et al., 2020</xref>). Therefore, regulators of histone modifications and chromatin dynamics, in particular, may be required for breast cancer progression. The identity of such regulators as well as strategies to therapeutically target them in the metastatic setting remain unclear.</p><p>Epigenetic regulators that are known to be involved in tumorigenesis include the KMT2 (also known as MLL/SET1) family protein complexes which mark active promoters and enhancers with histone H3 lysine K4 (H3K4) methylation and the non-specific lethal (NSL) complex which acetylates histones (<xref ref-type="bibr" rid="bib22">Dias et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Raja et al., 2010</xref>; <xref ref-type="bibr" rid="bib50">Ruthenburg et al., 2007</xref>; <xref ref-type="bibr" rid="bib54">Wysocka et al., 2005</xref>). WDR5 is a WD40 repeat protein that is a scaffold for the assembly of the KMT2 and NSL complexes (<xref ref-type="bibr" rid="bib28">Guarnaccia and Tansey, 2018</xref>). More recently, WDR5 was found to physically interact with the proto-oncogene and transcription factor MYC to guide its chromatin binding and transcriptional activation, suggesting that WDR5 is a tractable target for MYC-driven cancers (<xref ref-type="bibr" rid="bib51">Thomas et al., 2015a</xref>; <xref ref-type="bibr" rid="bib52">Thomas et al., 2015b</xref>). Aberrant WDR5 expression itself may occur in a number of cancer types (<xref ref-type="bibr" rid="bib18">Chen et al., 2015</xref>; <xref ref-type="bibr" rid="bib21">Dai et al., 2015</xref>; <xref ref-type="bibr" rid="bib24">Ge et al., 2016</xref>). Biologically, WDR5 may contribute to tumor sphere formation and cell proliferation (<xref ref-type="bibr" rid="bib17">Carugo et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Chung et al., 2016</xref>). Molecularly, WDR5 is reported to modulate the expression of various genes, which may be specific to cell type or cell state (<xref ref-type="bibr" rid="bib13">Bryan et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Oh et al., 2020</xref>). On the other hand, WDR5 was recently discovered to broadly regulate the expression of ribosomal protein (RP) genes across multiple cell lines and cancer types (<xref ref-type="bibr" rid="bib1">Aho et al., 2019</xref>; <xref ref-type="bibr" rid="bib13">Bryan et al., 2020</xref>; <xref ref-type="bibr" rid="bib29">Guarnaccia et al., 2021</xref>). Moreover, deregulation of RP gene expression and translation has been implicated in breast cancer metastasis (<xref ref-type="bibr" rid="bib23">Ebright et al., 2020</xref>). However, the relative importance of different WDR5 effector functions and their requirement for breast cancer progression and metastasis have not been well studied.</p><p>Here, we established an in vivo screening platform that identified WDR5 as a key regulator of breast cancer cell growth and metastatic colonization. We further showed that WDR5 regulates RP gene expression and global protein translation independently of the KMT2 complex. Moreover, our results indicate that WDR5 inhibition or degradation could be used as a therapeutic approach for TNBC and that WDR5 targeting could be combined with mTOR inhibitors to achieve significant therapeutic benefit.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>The establishment of in vivo lung metastasis screening platform</title><p>To identify actionable epigenetic targets for breast cancer metastasis, we conducted parallel in vivo and in vitro functional screens using an inducible, barcoded short hairpin RNA (shRNA) library (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We first compiled a list of epigenetic regulators based on: (1) if they could be targeted with existing pharmacological agents, (2) if their expression correlated with poor survival in multiple independent datasets (hazard ratio &gt;1 and p-value&lt;0.05), or (3) if their expression was increased in the lung metastatic cell subpopulation MDA-MB-231-LM2 (LM2) cells when compared to the parental TNBC cell line MDA-MB-231. We designed our screen using the LM2 cells because they reproducibly generate lung metastasis, and lung is the most frequent site of distant relapse in TNBC patients (<xref ref-type="bibr" rid="bib37">Lin et al., 2008</xref>; <xref ref-type="bibr" rid="bib41">Minn et al., 2005</xref>). Accordingly, we tested the knockdown efficiency of 327 shRNAs targeting 89 epigenetic regulators and selected one shRNA with the best knockdown efficiency per target gene (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>). We then subcloned these 89 shRNAs into the doxycycline (DOX) inducible and barcoded pINDUCER10 lentivirus to generate a focused knockdown-validated shRNA library (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>; <xref ref-type="bibr" rid="bib40">Meerbrey et al., 2011</xref>). Included in this library were positive control shRNAs against <italic>BUD31</italic> (shBUD31) and <italic>SAE2</italic> (shSAE2), which were previously shown to be essential for LM2 cell proliferation, along with shRNAs against <italic>CHEK1</italic> and <italic>STAMBP,</italic> which served as negative controls (<xref ref-type="bibr" rid="bib32">Hsu et al., 2015</xref>; <xref ref-type="bibr" rid="bib35">Kessler et al., 2012</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Decreasing WDR5 reduces breast cancer cell growth and lung metastasis.</title><p>(<bold>A</bold>) Schematic of in vivo and in vitro screening work flow. Epigenetic regulator inducible knockdown cell lines were mixed in equal numbers (pool of 8–10 lines) with control cell lines and injected into control or doxycycline (DOX) treated mice (625 mg/kg) intravenously or cultured under control or DOX (1 μg/mL) treated condition. Both lungs (in vivo) and cells (in vitro) were harvested for gDNA and subjected to barcode quantitative PCR as the screening output. (<bold>B</bold>) Volcano plot showing the results of the in vivo screen. Each data point is an average of 10–20 mice. Discovery hits are selected using p&lt;0.05 and log<sub>2</sub>FC (fold change)&gt;0.8 or log<sub>2</sub>FC &lt;−0.8. (<bold>C</bold>) Log<sub>2</sub>FC of the in vivo screen results versus log<sub>2</sub>FC of the in vitro screen results for each of the epigenetic regulators. Discovery hits are selected as in (<bold>B</bold>). (<bold>D</bold>) Western blot analysis of the indicated proteins in LM2 cells harboring inducible control (shCtrl) or WDR5 targeting (shWDR5-1 and shWDR5-2) shRNA after 3 days of DOX induction. (<bold>E</bold>) WST-1 proliferation assays of LM2 cells from (<bold>D</bold>) after indicated days of DOX treatment. Each symbol indicates mean ± SD for representative experiment performed in quadruplicate (n=4, unpaired two-side Student’s <italic>t</italic> test). ****p&lt;0.0001 (shCtrl versus shWDR5-1) and ****p&lt;0.0001 (shCtrl versus shWDR5-2). (<bold>F–G</bold>) Colony formation assays of LM2 cells from (<bold>D</bold>) after 9 days of either control or DOX treatment. Representative images (<bold>F</bold>) and quantification (<bold>G</bold>) are shown (n=3, unpaired two-side Student’s <italic>t</italic> test). p=0.057 (shCtrl −DOX versus shCtrl +DOX), ****p&lt;0.0001 (shWDR5-1 −DOX versus shWDR5−1 +DOX), and **p=0.0025 (shWDR5-2 −DOX versus shWDR5−2 +DOX). (<bold>H</bold>) Normalized bioluminescence unit (BLU) signals of lung metastasis of mice injected intravenously with LM2 cells from (<bold>D</bold>) and kept under DOX chow. The data represent mean ± SEM (shCtrl: n=6; shWDR5-1: n=7; shWDR5-2: n=5). **p=0.0012 (shCtrl versus shWDR5-1) and *p=0.017 (shCtrl versus shWDR5-2). (<bold>I–J</bold>) Box plots of relative BLU of indicated cell line at day 7 (<bold>I</bold>), p=0.1375 (shCtrl versus shWDR5-1), *p=0.0173 (shCtrl versus shWDR5-2), and day 50 (<bold>J</bold>), **p=0.0012 (shCtrl versus shWDR5-1), *p=0.017 (shCtrl versus shWDR5-2), post-injection normalized to its day 0 value. (<bold>K</bold>) Tumor volume measurements of mice injected into the fourth mammary fat pad with LM2 cells harboring inducible control or shWDR5-1. The data represent mean ± SEM. ****p&lt;0.0001 (shCtrl versus shWDR5-1). (<bold>L</bold>) Representative BLU images of mice in (<bold>K</bold>) at day 61. Significance determined using unpaired two-tailed Mann–Whitney test (shCtrl: n=14; shWDR5-1: n=13). *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001. For gel source data, see <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig1">Figure 1D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78163-fig1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78163-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>In vitro and in vivo distribution of positive control shRNAs and negative control shRNAs in pooled screens.</title><p>(<bold>A</bold>) Schematic representation of the pINDUCER10 plasmid. LTR, long terminal repeat; PSI, retroviral Ψ packaging element; RRE, Rev response element; TRE2, TRE2 promoter; Ubc, ubiquitin C promoter; rtTA3, reverse tetracycline-controlled transactivator 3; IRES, internal ribosome entry site; Puro, puromycin resistance. (<bold>B–C</bold>) Relative abundance of cells stably expressing positive control shRNAs against <italic>BUD31</italic> and <italic>SAE2</italic> (<bold>B</bold>) and negative control shRNAs against <italic>CHEK1</italic> and <italic>STAMBP</italic> (<bold>C</bold>) after the indicated days of in vitro culture under control or doxycycline (DOX) (1 μg/mL) treatment. Data normalized to abundance at the time of minipool mixture (day 0). Representative data are shown from one minipool experiment (n=4, unpaired two-side Student’s <italic>t</italic> test). (<bold>D</bold>) Representative data of lung metastasis signal from mice injected with a minipool and fed with either DOX (625 mg/kg) or regular chow at the indicated time point. ns, not significant. (<bold>E</bold>) Relative abundance of barcode for shRNA against <italic>WDR5</italic> and positive/negative controls in lung tissue from control and DOX-treated mice. (<bold>F</bold>) Representative image of primary tumor from mice injected into the fourth mammary fat pad with LM2 cells harboring inducible control or shWDR5-1 at day 62. (<bold>G</bold>) Quantification of primary tumor weight from mice in (<bold>F</bold>) at day 62. Each dot represents one tumor. (<bold>H</bold>) Relative bioluminescence units (BLU) of the primary tumors from mice in (<bold>F</bold>) at day 61 post-injection (shCtrl: n=14; shWDR5: n=13). (<bold>I–J</bold>) Quantification of ex vivo BLU signals of the lungs (<bold>I</bold>) and liver (<bold>J</bold>) from mice in (<bold>F</bold>) at day 62 post-injection. Each dot represents one animal (shCtrl: n=8; shWDR5: n=7). Significance determined using unpaired two-tailed Mann–Whitney test. *p&lt;0.05; **p&lt;0.001; ***p&lt;0.001; ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78163-fig1-figsupp1-v2.tif"/></fig></fig-group><p>LM2 cells were infected with individual shRNAs targeting 64 epigenetic regulators and control shRNA from this library. To ensure that any particular hairpin had enough representation and was above the detection limit for in vivo screening, a subset of knockdown cell lines against 8–10 epigenetic regulators and the control cell lines were combined together in equal numbers into seven minipools. We cultured these minipools in either control or DOX conditions for up to 10 doublings, then extracted gDNA from the pooled shRNA infected cells collected. Quantitative PCR (qPCR) analysis of gDNA confirmed that shBUD31 and shSAE2 were significantly depleted in the DOX-treated pools (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). On the other hand, the amount of shSTAMBP and shCHEK1 expressing cells did not change significantly in most control or DOX conditions, while shCHEK1 cells increased slightly after 10 days of DOX treatment (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). We next determined whether our controls perform similarly in vivo. Minipools were then injected intravenously and treated with either control or DOX (in animal chow for in vivo conditions). After 50 days, tumor-bearing lung tissue was collected and processed for gDNA extraction. We then compared the barcode abundance between control and DOX-treated lung tissue using qPCR analysis of gDNA. The results were normalized to the day 0 value.</p><p>We found that DOX treatment does not in itself affect the in vivo kinetics of lung metastatic growth (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). In a representative minipool, shBUD31 and shSAE2 consistently dropped-out in the DOX-treated condition, whereas shSTAMBP remained unchanged (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>). shCHEK1 was enriched significantly, which is likely indirectly due to the depletion of other shRNA expressing cell lines in the minipools (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>). From the in vivo screen, we identified 14 significant hits (p&lt;0.05, log<sub>2</sub>FC &gt;0.8 or log<sub>2</sub>FC &lt;−0.8, FC:+DOX/−DOX), and among these, 7 were drop-out hits where shRNA representation significantly decreased, while 7 were enrichment hits where shRNA representation significantly increased (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>). Many of these in vivo drop-out candidates were drop-out candidates in vitro (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>). For example, our screen identified drop-out shRNAs against MCM6, an essential eukaryotic genome replication factor, and CSNK2A1, previously shown to enhance metastatic growth of MDA-MB-231 cells (<xref ref-type="bibr" rid="bib7">Bae et al., 2016</xref>; <xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). Thus, many of these epigenetic targets may be, at least in part, required for the cell intrinsic fitness of metastatic cells.</p></sec><sec id="s2-2"><title>Decreasing WDR5 reduces breast cancer cell growth and lung metastasis</title><p>Among the top hits and potential therapeutic targets that were identified, we focused on WDR5 because it can be inhibited by small molecules, and shWDR5 was the second most significantly depleted shRNA in vivo (after shMCM6). WDR5 is known canonically as a scaffolding protein that recognizes and binds to methylated H3K4, allowing the modification of H3K4 trimethylation by the KMT2 protein complex (<xref ref-type="bibr" rid="bib54">Wysocka et al., 2005</xref>). More recently, WDR5 has been discovered to physically interact with and guide MYC to its transcriptional targets (<xref ref-type="bibr" rid="bib52">Thomas et al., 2015b</xref>). WDR5 has also been implicated in the growth of metastatic breast cancer cells, although the mechanism underlying this function of WDR5 is not clearly delineated (<xref ref-type="bibr" rid="bib47">Punzi et al., 2019</xref>).</p><p>We first confirmed the knockdown effect of WDR5 in individual unpooled LM2 cells and by using independent shRNAs against WDR5 (shWDR5-1 and shWDR5-2). Following 3 days of shRNA induction in vitro (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), both shRNAs against WDR5 caused a significant but modest decrease in cell proliferation when compared to a control shRNA (shCtrl) over 5 days (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). In addition, using long-term in vitro colony formation assays over 9 days, we found a profound impact of WDR5 knockdown on the in vitro clonogenic ability of LM2 cells (<xref ref-type="fig" rid="fig1">Figure 1F and G</xref>). We next asked whether both shRNAs affect lung metastasis outgrowth in vivo. We induced knockdown for 3 days in vitro before injecting LM2 cells into the tail vein of mice and monitoring lung metastatic colonization and outgrowth over 50 days. We observed a significant impairment on lung colonization by LM2 cells as early as day 7 post-injection (<xref ref-type="fig" rid="fig1">Figure 1H and I</xref>). At the end point (day 50), the average lung metastatic burden in the mice with shWDR5 cells was 5.7- or 16.5-fold lower than that in mice with LM2 cells expressing the control shRNA (<xref ref-type="fig" rid="fig1">Figure 1H and J</xref>). In addition to metastatic colonization from circulation, we tested whether knockdown of WDR5 affects tumor growth and metastasis from the orthotopic mammary fat pad. We observed a significant decrease in mammary tumor growth in the shWDR5 group compared to control tumors (<xref ref-type="fig" rid="fig1">Figure 1K and L</xref><bold>,</bold> <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F-H</xref>). Notably, we observed an even larger decrease in lung and liver metastasis from the mammary fat pad tumors in the shWDR5 group as compared to shCtrl, which suggests a potential metastasis-specific function of WDR5 (compare <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1I-J</xref> to <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H</xref>). Taken together, we showed that WDR5 is independently required for the cellular outgrowth, tumorigenic, and lung colonizing capacities of LM2 TNBC cells.</p></sec><sec id="s2-3"><title>WDR5 depletion significantly reduces breast cancer cell growth across multiple breast cancer subtypes</title><p>Next, we tested the requirement for WDR5 in other cell line models and from distinct breast cancer subtypes. To this end, we reduced WDR5 in additional breast cancer lines spanning three established molecular subtypes: TNBC (MDA-MB-453 and HCC1143), estrogen receptor positive (MCF7, T47D, and MDA-MB-361), and HER2+ (UACC893, BT474, and SKBR3) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). WDR5 knockdown significantly reduced the clonogenic outgrowth of all the tested cell lines (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>), suggesting that WDR5 enhances tumor cell growth across multiple breast cancer subtypes. As we were particularly interested in evaluating the therapeutic potential of targeting WDR5 in TNBC, we next tested the efficacy of a known WDR5 inhibitor, OICR-9429, which is a small molecule antagonist of the WDR5-KMT2 interaction (<xref ref-type="bibr" rid="bib26">Grebien et al., 2015</xref>). We treated LM2 cells with OICR-9429 at 20 μM for 9 days, and this also significantly reduced their colony formation ability (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>). Similar results were found when using OICR-9429 to treat two other TNBC cell lines, MDA-MB-453 and 4T1, although we noted that growth inhibition was more significant in MDA-MB-453 cells when using 30 μM of OICR-9429 (<xref ref-type="fig" rid="fig2">Figure 2F and G</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and B</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>WDR5 targeting significantly reduces breast cancer cell growth across breast cancer subtypes.</title><p>(<bold>A</bold>) Western blot analyses of WDR5 in the indicated cell lines infected with either control or WDR5-targeting hairpins with or without 3 days of doxycycline (DOX) (1 μg/mL) induction. (<bold>B–C</bold>) Colony formation assays of indicated control or shWDR5-1 cell lines from (<bold>A</bold>) after 9 days of DOX (1 μg/mL) treatment. Representative images (<bold>B</bold>) and quantification (<bold>C</bold>) are shown (n=3, unpaired two-side Student’s <italic>t</italic> test). **p<sub>MDA-MB-453</sub>=0.0011, ****p<sub>HCC1143</sub> &lt;0.0001, *p<sub>MCF7</sub>=0.0263, ****p<sub>T47D</sub>&lt;0.0001, ****p<sub>MDA-MB-361</sub>&lt;0.0001, **p<sub>UACC893</sub>=0.0017, ***p<sub>BT474</sub>=0.0004, and *p<sub>SKBR3</sub>=0.0156. Cell lines are grouped by breast cancer molecular subtype. (<bold>D–G</bold>) Colony formation assays of LM2 (<bold>D</bold>) and MDA-MB-453 (<bold>F</bold>) after 9 days of either control or OICR-9429 treatment at the indicated concentration. Representative images (D and F) and quantification (E and G) are shown (n=3, unpaired two-side Student’s <italic>t</italic> test). ****p<sub>LM2</sub> &lt;0.0001 (dimethyl sulfoxide (DMSO) versus OICR-9429 20 μM), **p<sub>MDA-MB-453</sub>=0.0018 (DMSO versus OICR-9429 20 μM), and ****p<sub>MDA-MB-453</sub>&lt;0.0001 (DMSO versus OICR-9429 30 μM). (<bold>H</bold>) Western blot analysis of WDR5 in LM2 cells treated with MS67, MS67N, or OICR-9429 at the indicated concentrations for 18 hr. Band intensities of WDR5 were quantified by image J and normalized by those of vinculin control. (<bold>I–J</bold>) Colony formation assays of LM2 after 9 days of treatment with control, OICR-9429, MS67N, or MS67 at the indicated concentrations. Representative images (<bold>I</bold>) and quantification (<bold>J</bold>) are shown (n=3, unpaired two-side Student’s <italic>t</italic> test). **p<sub>0.5μM</sub>=0.0012 (MS67N versus MS67), **p<sub>2.5μM</sub> = 0.0033 (DMSO versus OICR-9429), and ****p<sub>2.5μM</sub> &lt;0.0001 (MS67N versus MS67). For gel source data, see <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig2">Figure 2A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78163-fig2-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig2">Figure 2H</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78163-fig2-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78163-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>WDR5 inhibition and MS67-mediated WDR5 degradation significantly reduces breast cancer cell growth.</title><p>(<bold>A–B</bold>) Colony formation assays of 4T1 after 9 days of either control or 20 μM OICR-9429 treatment for 9 days. Representative images (<bold>A</bold>) and quantification (<bold>B</bold>) are shown (n=3, unpaired two-side Student’s <italic>t</italic> test). (<bold>C</bold>) Western blot analysis of WDR5 in MDA-MB-453 treated with MS67, MS67N, or OICR-9429 at the indicated concentrations for 18 hr. Band intensities were quantified by image J. (<bold>D–E</bold>) Western blot analysis of WDR5 in LM2 (<bold>D</bold>) or MDA-MB-453 (<bold>E</bold>) treated with 2.5 μM MS67 or MS67N for the indicated durations. Band intensities were quantified by image J and normalized by the those of vinculin control. (<bold>F–G</bold>) Colony formation assays of MDA-MB-453 after 9 days of treatment with control, OICR-9429, MS67N, or MS67 at the indicated concentrations. Representative images (<bold>F</bold>) and quantification (<bold>G</bold>) are shown (n=3, unpaired two-side Student’s <italic>t</italic> test). *p&lt;0.05; **p&lt;0.001; ***p&lt;0.001; ****p&lt;0.0001. For gel source data, see <xref ref-type="supplementary-material" rid="fig2s1sdata1">Figure 2—figure supplement 1—source data 1</xref>, <xref ref-type="supplementary-material" rid="fig2s1sdata2">Figure 2—figure supplement 1—source data 2</xref> and <xref ref-type="supplementary-material" rid="fig2s1sdata3">Figure 2—figure supplement 1—source data 3</xref>.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78163-fig2-figsupp1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78163-fig2-figsupp1-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata3"><label>Figure 2—figure supplement 1—source data 3.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78163-fig2-figsupp1-data3-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78163-fig2-figsupp1-v2.tif"/></fig></fig-group><p>As the effective concentration of OICR-9429 is relatively high and may lead to off-target effects, we sought to test the effect of our recently published WDR5 degrader MS67, which recruits WDR5 to Cullin4-CRBN E3 ubiquitin ligase complex for proteasome-mediated degradation (<xref ref-type="bibr" rid="bib56">Yu et al., 2021</xref>). We first evaluated the effect of MS67 on degrading WDR5 in LM2 and MDA-MB-453 cells. We found that MS67, but not the negative control MS67N, which does not bind to CRBN, nor OICR-9429, induced WDR5 degradation at a concentration as low as 0.02 μM (<xref ref-type="fig" rid="fig2">Figure 2H</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). Specifically, at 2.5 μM MS67, we achieved ~80% WDR5 degradation in LM2 cells and ~70% of degradation in MDA-MB-453 cells (<xref ref-type="fig" rid="fig2">Figure 2H</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). Additionally, the maximal degradation can be achieved at 8 hr post-treatment, and this effect remains stable for 72 hr in both LM2 and MDA-MB-453 cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D and E</xref>). Finally, we compared MS67-induced WDR5 degradation to OICR-9429 treatment on the clonogenic outgrowth of LM2 and MDA-MB-453 cells. We found that MS67 leads to ~50% growth inhibition at 0.5 μM and ~80% inhibition at 2.5 μM (<xref ref-type="fig" rid="fig2">Figure 2I and J</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F and G</xref>). Importantly, the effect of 2.5 μM MS67 treatment is comparable to shRNA knockdown and more potent than 20 μM OICR-9429 treatment in LM2 and MDA-MB-453 cells, while 2.5 μM of OICR-9429 treatment only caused a modest effect (compare <xref ref-type="fig" rid="fig1">Figures 1F, G</xref>, <xref ref-type="fig" rid="fig2">2B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F and G</xref>). In summary, MS67-mediated WDR5 degradation showed improved growth inhibition of breast cancer cells when compared to the OICR-9429 compound.</p></sec><sec id="s2-4"><title>WDR5 targeting decreases RP gene expression and global translation rates</title><p>To identify the molecular effects of WDR5 depletion in TNBC cells, we performed transcriptomic profiling of control and WDR5 knockdown cells. In addition to the MDA-MB-231 lung metastatic LM2 cells, we also tested the effect of WDR5 knockdown in independent MDA-MB-231 subpopulations that metastasize more readily to the brain (BrM3) or bone (BoM) (<xref ref-type="bibr" rid="bib12">Bos et al., 2009</xref>; <xref ref-type="bibr" rid="bib34">Kang et al., 2003</xref>). Because WDR5 has previously been shown to facilitate active transcription (<xref ref-type="bibr" rid="bib4">Ang et al., 2011</xref>; <xref ref-type="bibr" rid="bib54">Wysocka et al., 2005</xref>), we used spike-in RNA for normalization and found no changes in global RNA levels 3 days after shWDR5-1 induction (<xref ref-type="bibr" rid="bib33">Jiang et al., 2011</xref>). Our analyses identified differentially expressed genes (DEGs) in all three organotropic-metastatic cell subpopulations (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). In general, inhibition of WDR5 led to more down-regulated genes than up-regulated genes, which supports previous findings that WDR5 generally promotes transcriptional activation (<xref ref-type="bibr" rid="bib54">Wysocka et al., 2005</xref>; <xref ref-type="fig" rid="fig3">Figure 3A</xref>). Certain DEGs were preferentially regulated in LM2, BrM3, or BoM cells, suggesting that WDR5 can regulate genes in a manner that is dependent on the metastatic proclivities of different breast cancer cell subpopulations (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). On the other hand, we also found DEGs (264 down-regulated and 118 up-regulated) that were shared across all lines (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>), indicative of some conserved WDR5 function across metastatic breast cancer cells.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>WDR5 targeting decreases ribosomal protein (RP) gene expression and global translation rates.</title><p>(<bold>A</bold>) Bar graph summarizing the number of differentially expressed genes (DEGs) after WDR5 silencing across three MDA-MB-231 organotropic sublines (LM2-lung; BrM3-brain; BoM-bone). (<bold>B</bold>) Venn diagram showing the number of overlap or distinct down-regulated genes (left) and up-regulated genes (right) after WDR5 knockdown in the MDA-MB-231 organotropic sublines. (<bold>C</bold>) Gene ontology results using the down-regulated gene set shared by all three MDA-MB-231 organotropic sublines analyzed with Enrichr. (<bold>D</bold>) Volcano plot of DEGs after WDR5 knockdown in LM2. Shared DEGs across all lines highlighted in dark red and RP genes highlighted in light red. The top 10 differentially expressed RPs are labeled. (<bold>E</bold>) RT-quantitative PCR (qPCR) validation of selected DEGs in LM2 cells harboring shCtrl, shWDR5-1, or shWDR5-2 after doxycycline (DOX) (1 μg/mL) induction for 3 days. For <italic>WDR5</italic>, ****p&lt;0.0001 (shWDR5-1 −DOX versus +DOX) and ***p=0.0002 (shWDR5-2 −DOX versus +DOX); for <italic>RPL7</italic>, **p=0.0014 (shWDR5-1 −DOX versus +DOX), and **p=0.0012 (shWDR5-2 −DOX versus +DOX); for <italic>RPL9</italic>, *p=0.0106 (shWDR5-1 −DOX versus +DOX) and **p=0.0024 (shWDR5-2 -DOX versus +DOX); for <italic>RPL31</italic>, ***p=0.0007 (shWDR5-1 −DOX versus +DOX) and ****p&lt;0.0001 (shWDR5-2 −DOX versus +DOX); for <italic>RPL32</italic>, **p=0.0016 (shWDR5-1 −DOX versus +DOX) and **p=0.0018 (shWDR5-2 −DOX versus +DOX); for <italic>RPS14</italic>, **p=0.0015 (shWDR5-1 −DOX versus +DOX) and **p=0.0084 (shWDR5-2 −DOX versus +DOX). (<bold>F</bold>) RT-qPCR validation of selected DEGs in LM2 cells after DMSO or OICR-9429 treatments at the indicated concentration for 3 days. For <italic>RPL7</italic>, **p=0.0068 (DMSO versus OICR-9429 10 μM) and *p=0.0138 (DMSO versus OICR-9429 20 μM); for <italic>RPL32</italic>, *p0.0268 (DMSO versus OICR-9429 10 μM) and *p=0.0106 (DMSO versus OICR-9429 20 μM); for <italic>RPS14</italic>, **p=0.0032 (DMSO versus OICR-9429 10 μM) and **p=0.0024 (DMSO versus OICR-9429 20 μM). (<bold>G</bold>) RT-qPCR validation of selected DEGs in LM2 cells after DMSO, OICR-9429, MS67N, or MS67 treatments at the indicated concentration for 48 hr. Significance determined by comparing each treatment to DMSO control (n=4, unpaired two-side Student’s <italic>t</italic> test). For <italic>RPL32</italic>, *p=0.0171 (DMSO versus OICR-9429 2.5 μM), **p=0.0056 (DMSO versus MS67 0.5 μM), and **p=0.0031 (DMSO versus MS67 2.5 μM); for <italic>RPS14</italic>, **p=0.0068 (DMSO versus MS67N 0.5 μM), *p=0.0303 (DMSO versus MS67N 2.5 μM), and **p=0.0033 (DMSO versus MS67 2.5 μM). (<bold>H–J</bold>) Normalized translation rates as measured by incorporation of methionine analog homopropargylglycine (HPG) over time and evaluated by flow cytometry. Each data point represents the slope of HPG incorporation for at least three time points using median fluorescence intensity from an independent experiment. LM2 cells from (<bold>E</bold>) following 3 days of DOX (1 μg/mL) induction (<bold>H</bold>), ****p<sub>shWDR5-1</sub>&lt;0.0001, *p<sub>shWDR5-2</sub>=0.0230, LM2 cells following 3 days of control or OICR-9429 treatment at 20 μM (<bold>I</bold>), **p=0.0043, and LM2 cells following 3 days of MS67N or MS67 treatment at 2.5 μM (<bold>J</bold>), *p=0.0128, were tested. (n=3, one sample <italic>t</italic> test). *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78163-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>WDR5 targeting decreases ribosomal protein (RP) gene expression and global translation rates.</title><p>(<bold>A</bold>) Gene ontology results using the up-regulated gene set shared by three MDA-MB-231 organotropic sublines analyzed with Enrichr. (<bold>B–C</bold>) Volcano plot of genes differentially expressed after WDR5 knockdown in BrM3 (<bold>B</bold>) and BoM (<bold>C</bold>). Shared differentially expressed genes (DEGs) across all lines highlighted in dark red and RPs (RPL and RPS) highlighted in light red. The top 10 differentially expressed RPs are labeled. (<bold>D</bold>) RT-quantitative PCR (qPCR) validation of selected DEGs in MDA-MB-453 cells after control or OICR-9429 treatments at the indicated concentrations for 3 days. (<bold>E</bold>) RT-qPCR validation of selected DEGs in MDA-MB-453 cells after DMSO, 2.5 μM OICR-9429, MS67N, or MS67 treatment for 3 days. Significance determined by comparing each treatment to DMSO control (n=4, unpaired two-side Student’s <italic>t</italic> test). (<bold>F</bold>) Representative translation efficiency overtime using the indicated LM2 cell lines with continuous treatment of DOX (1 μg/mL). 100 μg/mL cycloheximide (CHX) was used as a control to completely block de novo protein translation. (<bold>G</bold>) Normalized translation rates of MDA-MB-453 cells following 3 days of control or 30 μM OICR-9429 treatment (n=4, one sample <italic>t</italic> test). Significance determined using one sample <italic>t</italic> test. *p&lt;0.05; **p&lt;0.001; ***p&lt;0.001; ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78163-fig3-figsupp1-v2.tif"/></fig></fig-group><p>We then performed Enrichr analysis on both the up- or down-regulated DEGs and found that the most enriched and significant gene ontology in the shared down-regulated DEGs was cytoplasmic RPs (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>). The combined score for this enrichment was 18-fold higher than the next enriched ontology for the shared down-regulated DEGs, demonstrating the significance of this WDR5 regulated pathway (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>). Notably, among the 474 down-regulated DEGs in LM2 cells, 51 (11%) encoded for RP genes (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). A similar enrichment pattern was observed in BrM3 and BoM cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B and C</xref>). After inducing WDR5 knockdown with both hairpins for 3 days in LM2 cells, we confirmed down-regulation of all the tested RP genes. These included the top two down-regulated RPs, <italic>RPL7</italic> and <italic>RPL31</italic>, which were consistently reduced by a ~50% (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). We next tested whether WDR5 targeting with either OICR-9429 or MS67 would have similar effects on gene expression. Treatment of LM2 and MDA-MB-453 cells with 10 or 20 μM of OICR-9429 for 3 days decreased <italic>RPL7</italic> and other RP genes as predicted (<xref ref-type="fig" rid="fig3">Figure 3F</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). We next evaluated the gene-regulatory effect of MS67, which is a more effective inhibitor of WDR5. MS67 treatment at 2.5 μM significantly down-regulate several RP genes whereas OICR-9429 and MS67N did not have as significant of an effect at these lower concentrations (<xref ref-type="fig" rid="fig3">Figure 3G</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). As down-regulation of RP genes expression implies a decrease in ribosome biogenesis, we also measured protein translation rates in TNBC cells where WDR5 was pharmacologically or genetically blocked. Accordingly, WDR5 silencing impaired global protein translation rates (<xref ref-type="fig" rid="fig3">Figure 3H</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>). OICR-9429 treatment or MS67-mediated degradation also caused decreases in protein translation in both LM2 and MDA-MB-453 cell lines (<xref ref-type="fig" rid="fig3">Figure 3I and J</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G</xref>). Taken together, our data demonstrates that either genetic or pharmacological inhibition of WDR5 can suppress RP gene expression and global translation in breast cancer cells.</p></sec><sec id="s2-5"><title>The WDR5-binding motif (WBM)-binding sites are required for WDR5-dependent cell growth and RP gene expression</title><p>We next sought to identify which of WDR5’s multiple molecular function(s) is required for RP gene expression and breast cancer cell growth. WDR5 is canonically part of the mammalian KMT2A complex, which also consists of WRAD proteins (WDR5, RBBP5, ASH2L, and DPY30). Only KMT2A and RBBP5 interact directly with WDR5, and the complex has recently been elucidated by cryo-electron microscopy (<xref ref-type="bibr" rid="bib45">Park et al., 2019</xref>; <xref ref-type="fig" rid="fig4">Figure 4A</xref>). WDR5 is a donut-shaped protein with two important binding pockets, WDR5-interacting (WIN) and WBM (<xref ref-type="bibr" rid="bib28">Guarnaccia and Tansey, 2018</xref>; <xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). KMT2A binding to the WIN site can be disrupted by point mutation F133A on WDR5 (<xref ref-type="bibr" rid="bib29">Guarnaccia et al., 2021</xref>; <xref ref-type="bibr" rid="bib46">Patel et al., 2008</xref>). On the other hand, RBBP5 and c-MYC have been shown to bind at the WBM site, which can be disrupted by point mutations N225A and V268E (<xref ref-type="bibr" rid="bib29">Guarnaccia et al., 2021</xref>; <xref ref-type="bibr" rid="bib52">Thomas et al., 2015b</xref>). In addition to the F133A, N225A, and V268E mutants, WDR5 mutants K7Q and 1-25Δ were recently shown to specifically impact ciliogenesis (<xref ref-type="bibr" rid="bib36">Kulkarni et al., 2018</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The WBM-binding sites are required for WDR5-dependent cell growth and ribosomal protein gene expression.</title><p>(<bold>A</bold>) WDR5 protein structure and key residues in the WIN and WBM sites that interact with binding partners. (<bold>B</bold>) Schematic of WDR5 with the indicated mutation sites. (<bold>C</bold>) Western blot analysis of the indicated proteins in LM2 inducible shWDR5 cells over-expressing wild-type (WT) WDR5 or WDR5 mutants. Cells were collected after 3 days of control or doxycycline (DOX) (1 μg/mL) induction. (<bold>D</bold>) Western blot analysis of the indicated proteins after immunoprecipitation using anti-Flag antibody in the LM2 shWDR5 cells over-expressing green fluorescent protein (GFP), WT WDR5, or WDR5 mutants. (<bold>E–F</bold>) Colony formation assays of cells expressing GFP, WT WDR5, or WDR5 mutants in inducible shControl (shCtrl) or shWDR5 cell lines after 9 days of control or DOX treatment. Representative images (<bold>E</bold>) and quantification (<bold>F</bold>) are shown. DOX-treated wells were compared to their respective controls for each cell line (n=3, unpaired two-side Student’s <italic>t</italic> test). p<sub>WT</sub> = 0.4047, ***p<sub>GFP</sub> = 0.0002, p<sub>1-25Δ</sub>=0.0854, *p<sub>K7Q</sub>=0.0104, p<sub>F133A</sub>=0.8448, **p<sub>N225A</sub>=0.0014, and **p<sub>V268E</sub>=0.0027. (<bold>G</bold>) RT-quantitative PCR analysis of the indicated mRNAs in LM2 from (<bold>E</bold>) induced with DOX (1 μg/mL) for 3 days. Significance determined by comparing each treatment to WT control (n=4, unpaired two-side Student’s <italic>t</italic> test). For <italic>RPL9</italic>, ****p<sub>GFP</sub> &lt;0.0001, ****p<sub>1-25Δ</sub>&lt;0.0001, ***p<sub>K7Q</sub>=0.0002, ****p<sub>N225A</sub>&lt;0.0001, and ***p<sub>V268E</sub>=0.0006; for <italic>RPL31</italic>, **p<sub>GFP</sub> = 0.0045, ***p<sub>1-25Δ</sub>=0.0007, **p<sub>K7Q</sub>=0.0027, **p<sub>N225A</sub>=0.0027, and *p<sub>V268E</sub>=0.0307; for <italic>RPS14</italic>, ****p<sub>GFP</sub> &lt;0.0001, ****p<sub>1-25Δ</sub>&lt;0.0001, ****p<sub>K7Q</sub>&lt;0.0001, ****p<sub>N225A</sub>&lt;0.0001, and ***p<sub>V268E</sub>=0.0005. For gel source data, see <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78163-fig4-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78163-fig4-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78163-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>WDR5 recruitment to ribosomal protein gene promoters is not sufficient for gene activation.</title><p>(<bold>A–B</bold>) Chromatin immunoprecipitation (ChIP)-quantitative PCR data of the indicated over-expression condition using primers for either the promoter or 800 bp downstream control at the RPL7 (left) or RPL31 (right) gene locus. ChIP was performed using the anti-Flag to pull down WDR5 (<bold>A</bold>) and H3K4me3 (<bold>B</bold>). Significance determined by comparing promoter enrichment of WT to other over-expressing conditions using unpaired two-tailed Student’s <italic>t</italic> test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78163-fig4-figsupp1-v2.tif"/></fig></fig-group><p>Based on this information, we performed a structure function analysis of WDR5 by constitutively expressing shRNA-resistant wild-type (WT) WDR5 or the aforementioned WDR5 mutants with C-terminal 3XFlag-tag in LM2 cells, where endogenous <italic>WDR5</italic> was concomitantly reduced. Following DOX induction, we confirmed ectopic WDR5 (mutant or WT) expression in the indicated mutant cell lines, whereas endogenous WDR5 levels were significantly repressed (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Using co-immunoprecipitation (Co-IP) assays, we observed that the F133A but not N25A or V268E mutations abrogate the binding of WDR5 to KMT2A. In contrast, mutants N225A and V268E but not F133A reduced the binding of WDR5 to RBBP5 by more than 50% as expected (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). We next determined which WDR5 interacting site is required for cell growth. Consistently, shWDR5 cells expressing GFP control had severely impacted colony formation, while expression of WT WDR5 rescued this growth defect (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>). The N-terminal mutant 1-25Δ or K7Q has either a similar or slightly lower ability to rescue WDR5-dependent cell growth, respectively. Surprisingly, the WIN site mutant F133A was able to rescue the colony formation phenotype, while neither N225A nor V268E effectively rescued cell growth. These results suggest that the WBM but not the WIN-binding ability of WDR5 is required for WDR5-dependent growth of TNBC cells.</p><p>We next tested whether the different WDR5 mutants affected WDR5 binding to the promoter of RP genes and alter H3K4me3 levels in LM2 cells. Chromatin immunoprecipitation and qPCR (ChIP-qPCR) analysis showed that the F133A mutant binds to the promoter of <italic>RPL7</italic> and <italic>RPL31</italic> less efficiently, while N225A and V268E mutants bind chromatin similarly as the WT protein (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Surprisingly, all mutants maintained a similar level of H3K4me3 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), suggesting that WDR5 binding to chromatin is not required for maintaining H3K4me3 at the RP gene promoters tested in this context. More importantly, the N-terminal and F133A mutants rescued the expression of <italic>RP</italic> genes<italic>,</italic> whereas the N225A and V268E mutants did not (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). Altogether, these data suggest that, in LM2 cells, WBM but not WIN binding by WDR5 is important for the maintenance of RP gene expression.</p></sec><sec id="s2-6"><title>Metastatic cell growth and lung colonization do not require the KMT2 complex components</title><p>The surprising observation that WIN binding by WDR5 is dispensable for breast cancer cell growth prompted us to directly test the requirement for the canonical KMT2 complex components in LM2 cells (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). We first confirmed efficient knockdown of seven complex components (KMT2A, RBBP5, DPY30, HCFC1, CXXC1, WDR82, and BOD1L1), each with two independent shRNA after 3 days of DOX induction (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). We first directly asked if KMT2A is required for LM2 cell growth and lung metastasis as KMT2A is a catalytic subunit of the H3K4 methyltransferase complex and was seemingly depleted in our screen (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). However, depleting KMT2A with multiple shRNAs did not reproducibly affect in vitro colony formation and in vivo lung metastasis growth (<xref ref-type="fig" rid="fig5">Figure 5D–F</xref>). This result is also consistent with the phenotype observed from the F133A mutant and suggests that KMT2A is dispensable for WDR5-dependent cell growth. We next assessed whether RBBP5, DPY30, and HCFC1 are required for RP gene expression and cell growth. RP gene expression was not changed after knockdown of RBBP5, DPY30, or HCFC1 (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Furthermore, most of these KMT2 complex components are not required for the growth of LM2 cells (<xref ref-type="fig" rid="fig5">Figure 5H and I</xref>). The exception was upon knockdown of HCFC1 which resulted in a 40% decrease in colony formation (<xref ref-type="fig" rid="fig5">Figure 5H and I</xref>), likely due to the role of HCFC1 in cell cycle control (<xref ref-type="bibr" rid="bib5">Antonova et al., 2019</xref>; <xref ref-type="bibr" rid="bib55">Xiang et al., 2020</xref>). While RBBP5, DPY30, and HCFC1 are common to the KMT2 complexes, CXXC1 and WDR82 are distinct to the SET1A/B complexes, and BOD1L1 is specific to the SET1B complex (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Thus, we asked whether WDR5 regulates the growth phenotype specifically through SET1A/B complexes by perturbing CXXC1, WDR82, or BOD1L1. However, knockdown of these components also did not decrease RP gene expression and colony formation (<xref ref-type="fig" rid="fig5">Figure 5G–I</xref>). Therefore, the KMT2 complexes are not the major effectors of WDR5-dependent metastatic cell growth in the LM2 model.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Metastatic cell growth and lung colonization do not require KMT2 complex components.</title><p>(<bold>A</bold>) Schematic of subunit composition of several KMT2 complexes. (<bold>B</bold>) Western blot analyses of the indicated proteins in LM2 cells transduced with inducible shRNA targeting KMT2A, RBBP5, DPY30, HCFC1, CXXC1, and WDR82. Cells were collected after 3 days of doxycycline (DOX) (1 μg/mL) treatment. (<bold>C</bold>) RT-quantitative PCR (qPCR) analysis of <italic>BOD1L1</italic> in LM2 cells transduced with two independent hairpins targeting <italic>BOD1L1</italic>. Cells were collected after 3 days of DOX treatment (n=4, unpaired two-side Student’s <italic>t</italic> test). (<bold>D–E</bold>) Colony formation assay of LM2 shCtrl or shKMT2A cells (shKMT2A-1 and shKMT2A-2) after 9 days of treatment with control or DOX. Representative images (<bold>D</bold>) and quantification (<bold>E</bold>) are shown (n=3, unpaired two-side Student’s <italic>t</italic> test). (<bold>F</bold>) Normalized bioluminescence unit (BLU) signals of lung metastasis at day 66 of mice injected intravenously with LM2 cells from (<bold>B</bold>) and fed with DOX chow. The data represent mean ± SEM. Significance determined using unpaired two-tailed Mann–Whitney test. ns, not significant; p=0.2857 (shCtrl versus shKMT2A-1) and p=0.5556 (shCtrl versus shKMT2A-2). (<bold>G</bold>) RT-qPCR analysis of the noted RP genes in LM2 cells transduced with the indicated inducible shRNAs. Cells were collected after 3 days of DOX treatment. Significance determined by comparing each treatment to shCtrl. (<bold>H–I</bold>) Colony formation assay of LM2 cells from (<bold>G</bold>) after 9 days of either control or DOX treatment. Representative images (<bold>H</bold>) and quantification (<bold>I</bold>) are shown (n=3, unpaired two-side Student’s <italic>t</italic> test). ***p=0.0005 (shHCFC1 #1 −DOX versus shHCFC1 #1 +DOX) and **p=0.0039 (shHCFC1 #2 −DOX versus shHCFC1 #2 +DOX). For gel source data, see <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig5">Figure 5B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78163-fig5-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78163-fig5-v2.tif"/></fig></sec><sec id="s2-7"><title>Inhibition of WDR5 and mTOR cooperatively reduces translation and TNBC growth</title><p>Hyperactivation of growth signaling pathways can increase protein synthesis, and inhibition of translation is being actively explored as a therapeutic avenue for cancer treatment (<xref ref-type="bibr" rid="bib10">Bhat et al., 2015</xref>; <xref ref-type="bibr" rid="bib27">Grzmil and Hemmings, 2012</xref>). Several mTOR inhibitors have been approved or are being tested in clinal trials, including the first generation mTOR inhibitors, everolimus and temsirolimus, and the second generation mTOR inhibitor, OSI-027 (<xref ref-type="bibr" rid="bib58">Zheng and Jiang, 2015</xref>). Everolimus and temsirolimus are rapalogs that allosterically inhibit mTORC1, while OSI-027 is an ATP-competitive inhibitor that inhibits both mTORC1 and mTOCR2 (<xref ref-type="bibr" rid="bib58">Zheng and Jiang, 2015</xref>). Everolimus has been approved to treat post-menopausal women with advanced hormone receptor positive, HER2 negative breast cancer in combination with an aromatase inhibitor exemestane (<xref ref-type="bibr" rid="bib9">Baselga et al., 2012</xref>). Because cancer cells could develop resistance to inhibitors of protein translation and this class of drugs may not directly cause tumor cell death (<xref ref-type="bibr" rid="bib49">Rozengurt et al., 2014</xref>; <xref ref-type="bibr" rid="bib58">Zheng and Jiang, 2015</xref>), identifying other regimens which synergize with mTOR inhibitors is warranted.</p><p>Interestingly, during the course of titrating mTOR inhibitors in our cell model, we noted that the treatment with OSI-027 or everolimus alone caused an up-regulation of RP gene expression (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A-D</xref>), which may be due to an adaptive feedback effect on proteostasis following mTOR inhibition. Importantly, treatment with the WDR5 inhibitor OICR-9429 partially or completely blocked this adaptive induction of RP genes (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A and B</xref>). Moreover, while mTOR inhibitors were confirmed to down-regulate phosphorylated S6 protein kinase (S6K) and translation initiation factor 4E binding protein 1 (4E-BP1), WDR5 inhibition reduced RP genes expression and translation independently of this signaling pathway (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E and F</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Inhibition of WDR5 and mTOR cooperatively reduces translation and triple-negative breast cancer (TNBC) cell growth.</title><p>(<bold>A</bold>) Western blot analysis of the indicated proteins in LM2 cells treated for 3 days with or without 20 μM OICR-9429 in combination with control, 2 μM OSI-027, 2.5 μM temsirolimus, or 5 nM everolimus. (<bold>B</bold>) Western blot analysis of the indicated proteins in MDA-MB-453 treated for 3 days with or without 30 μM OICR-9429 in combination with control, 0.5 μM OSI-027, or 1 nM everolimus. (<bold>C</bold>) Normalized translational rates in LM2 cells from (<bold>A</bold>) (n=3, one sample <italic>t</italic> test). *p=0.0166 (DMSO versus OICR-9429), ***p=0.0001 (DMSO versus OSI-027), ** p=0.0099 (DMSO versus OICR-9429 +OSI-027), **p=0.0080 (DMSO versus everolimus), **p=0.0047 (DMSO versus OICR-9429+), *p=0.0232 (OSI-027 versus OICR-9429 +OSI-027), and *p=0.00352 (everolimus versus OICR-9429 +everolimus). (<bold>D</bold>) Normalized translational rates in MDA-MB-453 cells from (<bold>B</bold>) (n=3, one sample <italic>t</italic> test). *p=0.0107 (DMSO versus OICR-9429), ****p&lt;0.0001 (DMSO versus OSI-027), ****p&lt;0.0001 (DMSO versus OICR-9429 +OSI-027), **p=0.0012 (DMSO versus everolimus), ***p=0.0005 (DMSO versus OICR-9429 +everolimus), ****p&lt;0.0001 (OSI-027 versus OICR-9429 +OSI-027), and *p=0.0370 (everolimus versus OICR-9429 +everolimus). (<bold>E–F</bold>) Colony formation assay of LM2 treated for 8 days with or without 20 μM OICR-9429 in combination with control or 2 μM OSI-027. Representative images (<bold>E</bold>) and quantification (<bold>F</bold>) are shown. ****p&lt;0.0001 (DMSO versus OICR-9429), ****p&lt;0.0001 (DMSO versus OSI-027), ****p&lt;0.0001 (DMSO versus OICR-9429 +OSI-027), ****p&lt;0.0001 (OICR-9429 versus OICR-9429 +OSI-027), and *p=0.0233 (OSI-027 versus OICR-9429 +OSI-027). (<bold>G–H</bold>) Colony formation assay of LM2 cells treated for 8 days with or without 20 μM OICR-9429 in combination with control or 5 nM everolimus. Representative images (<bold>G</bold>) and quantification (<bold>H</bold>) are shown. **p=0.0043 (DMSO versus OICR-9429), **p=0.0011 (DMSO versus everolimus), ***p=0.0004 (DMSO versus OICR-9429 +everolimus), **p=0.0042 (OICR-9429 versus OICR-9429 +everolimus), and *p=0.0272 (everolimus versus OICR-9429 +everolimus). (<bold>I–J</bold>) Colony formation assay of MDA-MB-453 treated for 10 days with or without 30 μM OICR-9429 in combination with control or 0.5 μM OSI-027. Representative images (<bold>I</bold>) and quantification (<bold>J</bold>) are shown. **p=0.0018 (DMSO versus OICR-9429), ***p=0.0009 (DMSO versus OSI-027), ****p&lt;0.0001 (DMSO versus OICR-9429 +OSI-027), ****p&lt;0.0001 (OICR-9429 versus OICR-9429 +OSI-027), and *p=0.011 (OSI-027 versus OICR-9429 +OSI-027). (<bold>K–L</bold>) Colony formation assay of MDA-MB-453 cells treated for 10 days with or without 30 μM OICR-9429 in combination with control or 1 nM everolimus. Representative images (<bold>K</bold>) and quantification (<bold>L</bold>) are shown (n=3, unpaired two-side Student’s <italic>t</italic> test). ***p=0.0002 (DMSO versus OICR-9429), ***p=0.0002 (DMSO versus everolimus), ****p&lt;0.0001 (DMSO versus OICR-9429 +everolimus), ****p&lt;0.0001 (OICR-9429 versus OICR-9429 +everolimus), and ***p=0.0003 (everolimus versus OICR-9429 +everolimus). Calculation of coefficients of drug interaction (CDIs) is described in Materials and methods section. Significant synergy is labeled with (#). For gel source data, see <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig6sdata2">Figure 6—source data 2</xref>.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig6">Figure 6A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78163-fig6-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig6">Figure 6B.</xref></title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78163-fig6-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78163-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Inhibition of WDR5 and mTOR cooperatively reduces translation and triple-negative breast cancer (TNBC) growth.</title><p>(<bold>A</bold>) RT-quantitative PCR (qPCR) of selected differentially expressed genes (DEGs) in LM2 after DMSO, 2 μM OSI-027, 20 μM OICR-9429, or combined treatment for 3 days. (<bold>B</bold>) RT-qPCR of selected DEGs in MDA-MB-453 after DMSO, 0.5 μM OSI-027, 30 μM OICR-9429, or combined treatment for 3 days. (<bold>C</bold>) RT-qPCR of selected DEGs in LM2 after DMSO or 5 nM everolimus treatment for 3 days. (<bold>D</bold>) RT-qPCR of selected DEGs in MDA-MB-453 after DMSO or 1 nM everolimus treatment for 3 days. Significance determined by comparing each treatment to DMSO control (n=4, unpaired two-side Student’s <italic>t</italic> test). (<bold>E</bold>) Western blot analysis of the indicated proteins in LM2 shCtrl, shWDR5-1, and shWDR5-2 with or without hairpin induction by doxycycline (DOX) (1 μg/mL) for 3 days. (<bold>F</bold>) Western blot analysis of indicated proteins in LM2 shWDR5-1 with or without DOX (1 μg/mL) induction in combination with 3 days of control, 2 μM OSI-027, or 5 nM everolimus treatment. (<bold>G</bold>) Normalized translational rates of LM2 shWDR5 cells from (<bold>A</bold>) following 3 days of control, 2 μM OSI-027, or 5 nM everolimus treatment (n=3, one sample <italic>t</italic> test). (<bold>H–I</bold>) Colony formation assay of LM2 shWDR5 with or without hairpin induction by DOX in combination with control or 2 μM OSI-027 treatment for 8 days. Representative images (<bold>H</bold>) and quantification (<bold>I</bold>) are shown. (<bold>J–K</bold>) Colony formation assay of LM2 shWDR5 cells with or without hairpin induction by DOX in combination with control or 5 nM everolimus treatment for 8 days. Representative images (<bold>J</bold>) and quantification (<bold>K</bold>) are shown. (<bold>L–M</bold>) Colony formation assay of LM2 with or without 20 μM OICR-9429 in combination with control or 2.5 μM temsirolimus treatment for 8 days. Representative images (<bold>M</bold>) and quantification (<bold>L</bold>) are shown (n=3, unpaired two-side Student’s <italic>t</italic> test). *p&lt;0.05; **p&lt;0.001; ***p&lt;0.001; ****p&lt;0.0001. Calculation of coefficients of drug interaction (CDIs) is described in Materials and methods section. Significant synergy is labeled with (#). For gel source data, see <xref ref-type="supplementary-material" rid="fig6s1sdata1">Figure 6—figure supplement 1—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig6s1sdata2">Figure 6—figure supplement 1—source data 2</xref>.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78163-fig6-figsupp1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata2"><label>Figure 6—figure supplement 1—source data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F.</xref></title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78163-fig6-figsupp1-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78163-fig6-figsupp1-v2.tif"/></fig></fig-group><p>Based on these results, we postulated that the inhibition of WDR5 and mTOR could cooperatively decrease TNBC protein translation, cell growth, and survival. As such we first treated LM2 and MDA-MB-453 cells for 3 days using OICR-4129 or the three mTOR inhibitors, everolimus, temsirolimus, and OSI-027. The levels of phosphorylated S6K and translation initiation factor 4E-BP1 were decreased in both cell lines after everolimus or temsirolimus treatment, while OSI-027 treatment only showed strong inhibition of mTOR signaling in the MDA-MB-453 cells (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). Similar mTOR signaling inhibition was observed in LM2 cells expressing shWDR5, confirming that mTOR regulation is independent of WDR5 (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>). Next, we compared the global translation rates of LM2 or MDA-MB-453 cells, when WDR5 was inhibited genetically or pharmacologically in combination with mTOR inhibitors OSI-027 or everolimus. The overall translation was decreased when combining WDR5 inhibition or WDR5 knockdown with mTOR inhibition (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1G</xref>). This combinatorial effect on protein translation correlated with an additive inhibition of clonogenic outgrowth (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1H–1K</xref>). Moreover, both OSI-027 and everolimus act synergistically with WDR5 inhibition in both LM2 and MDA-MB-453 cells (<xref ref-type="fig" rid="fig6">Figure 6E-L</xref>), while temsirolimus showed an additive effect in LM2 cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1L and M</xref>). We next tested the effects of MS67-mediated WDR5 degradation in combination with mTOR inhibition. MS67 treatment alone also did not affect mTOR signaling (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>). Interestingly, MS67 acts synergistically with both OSI-027 and everolimus in inhibiting translation in MDA-MB-453 cells (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Furthermore, we found that 5 µM MS67 is more effective than 20 µM OICR-9429 at inhibiting colony outgrowth when combined with either OSI-027 or everolimus in LM2 cells (compare <xref ref-type="fig" rid="fig6">Figure 6E–H</xref> to <xref ref-type="fig" rid="fig7">Figure 7D–G</xref>). Importantly, we found that OSI-027 had better synergistic effects (based on coefficients of drug interactions) with WDR5 inhibition when compared to everolimus (<xref ref-type="fig" rid="fig7">Figure 7D–G</xref>), suggesting that mTORC2 could be critical for clonogenic outgrowth in the context of WDR5 inhibition. Moreover, we observed increased cleaved caspase 3 level in the combined treatment group in MDA-MB-453 cells (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), suggesting the combination of WDR5 inhibition and OSI-027 induces apoptosis.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>MS67-mediated WDR5 degradation and mTOR inhibition cooperatively reduces translation and triple-negative breast cancer (TNBC) cell growth.</title><p>(<bold>A</bold>) Western blot analysis of the indicated proteins in LM2 cells treated for 3 days with 2.5 μM MS67N or MS67 in combination control, 2 μM OSI-027, or 5 nM everolimus. (<bold>B</bold>) Western blot analysis of the indicated proteins in MDA-MB-453 cells treated for 3 days with 2.5 μM MS67N or MS67 in combination with control, 0.5 μM OSI-027, or 1 nM everolimus. (<bold>C</bold>) Normalized translational rates in MDA-MB-453 cells from (<bold>B</bold>) (n=3, one sample <italic>t</italic> test). *p=0.0209 (MS67N versus MS67), ****p&lt;0.0001 (MS67N versus MS67N +OSI-027), ****p&lt;0.0001 (MS67N versus MS67 +OSI-027), ****p&lt;0.0001 (MS67N versus MS67N +everolimus), ****p&lt;0.0001 (MS67N versus MS67 +everolimus), ****p&lt;0.0001(MS67N +OSI-027 versus MS67 +OSI-027), and ****p&lt;0.0001(MS67N +everolimus versus MS67 +everolimus). (<bold>D–E</bold>) Colony formation assay of LM2 cells treated for 9 days with 5 μM MS67N or MS67 in combination with control or 2 μM OSI-027. Representative images (<bold>D</bold>) and quantification (<bold>E</bold>) are shown. ****p&lt;0.0001 (MS67N versus MS67), ****p&lt;0.0001 (MS67N versus MS67N+OSI-027), ****p&lt;0.0001 (MS67N versus MS67 +OSI-027), ***p=0.0004 (MS67 versus MS67 +OSI-027), and ****p&lt;0.0001 (MS67N+OSI-027 versus MS67 +OSI027). (<bold>F–G</bold>) Colony formation assay of LM2 cells with 5 μM MS67N or MS67 in combination with control or 5 nM everolimus for 9 days. Representative images (<bold>F</bold>) and quantification (<bold>G</bold>) are shown. ***p=0.0005 (MS67N versus MS67), ***p=0.0004 (MS67N versus MS67N +everolimus), ***p=0.0002 (MS67N versus MS67 +everolimus), ***p=0.0003 (MS67 versus MS67 +everolimus), and ***p=0.0008 (MS67N +everolimus versus MS67 +everolimus). (n=3, unpaired two-side Student’s <italic>t</italic> test). *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001. Calculation of coefficients of drug interaction (CDIs) is described in Materials and methods section. Significant synergy is labeled with (#). For gel source data, see <xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig7sdata2">Figure 7—source data 2</xref>.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig7">Figure 7A.</xref></title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78163-fig7-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig7">Figure 7B.</xref></title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78163-fig7-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78163-fig7-v2.tif"/></fig><p>Collectively, our data identified WDR5-mediated protein translation as a potential vulnerability, which could be therapeutically leveraged in TNBC cells treated with first- or second-generation mTOR inhibitors.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Epigenetic aberrations contribute to multiple steps of tumor initiation, cancer invasion and migration, and tumor outgrowth through a wide spectrum of mechanisms (<xref ref-type="bibr" rid="bib11">Blair and Yan, 2012</xref>; <xref ref-type="bibr" rid="bib19">Chen and Yan, 2021</xref>). Moreover, recent efforts have led to the development of multiple pharmacological agents designed to target epigenetic and chromatin-modifying proteins in cancer (<xref ref-type="bibr" rid="bib2">Ahuja et al., 2016</xref>; <xref ref-type="bibr" rid="bib38">Lu et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">Zhou et al., 2020</xref>). Nevertheless, it is unclear how such agents can be leveraged therapeutically as single agents or in combination, particularly for the treatment of breast cancers. In this study, we performed an in vivo functional screen of epigenetic factors to identify WDR5 as being required for metastatic breast cancer growth. Intriguingly, WDR5 regulates ribosomal gene expression independent of its H3K4 methylation activity but through its WBM domain to mediate translation rate and cell growth. WDR5 inhibition or degradation suppresses translation and growth of breast cancer cells, alone or in combination with mTOR inhibitors. These results indicate that WDR5 promotes breast cancer growth and metastasis through regulating translation.</p><p>WDR5 is best known for its role in the KMT2 complexes, which promote transcription through H3K4 methylation (<xref ref-type="bibr" rid="bib54">Wysocka et al., 2005</xref>). Unexpectedly, our structure function studies using the F133A WDR5 mutant suggest that KMT2 binding may not be critical for WDR5-mediated ribosomal gene expression and cell growth by metastatic TNBC cells. Consistently, depletion of several other components of the KMT2 complex did not affect the fitness of metastatic TNBC cells. These results suggest that WDR5 regulates translation and growth through KMT2 enzymatic activity-independent function. However, we showed that WIN site inhibitor OCIR-9429 suppresses RP gene expression and protein translation, suggesting that it exerts its effects through different mechanisms. It was reported that WIN site inhibitors C3 and C6 can displace WDR5 from the chromatin (<xref ref-type="bibr" rid="bib1">Aho et al., 2019</xref>; <xref ref-type="bibr" rid="bib13">Bryan et al., 2020</xref>), suggesting that OCIR-9429 may have similar activity. In addition, WIN site inhibitors may disrupt binding of proteins to the WBM site via allosteric effects, although C6 does not disrupt the binding between WDR5 and Myc or RBBP5 (<xref ref-type="bibr" rid="bib29">Guarnaccia et al., 2021</xref>). These possibilities will need to be further investigated in future studies.</p><p>WDR5 can also be recruited to the NSL complex with the acetyltransferase male of the first (MOF), and WDR5 directly interacts with the subunit KANSL1 and KANSL2 through the WIN and WBM sites, respectively (<xref ref-type="bibr" rid="bib22">Dias et al., 2014</xref>). The interaction of KANSL1 with WDR5 is important for efficient targeting of NSL complex to the promoter of target genes (<xref ref-type="bibr" rid="bib22">Dias et al., 2014</xref>). Therefore, it is likely that the NSL complex does not contribute to these phenotypes as WIN site WDR5 mutant F133A did not show a defective growth phenotype in this context. Alternatively, WDR5 likely regulates the phenotype described herein through a non-canonical function, such as its known ability to recruit the transcription factor MYC (<xref ref-type="bibr" rid="bib52">Thomas et al., 2015b</xref>). WDR5 was previously shown to directly interact with MYC through the WBM site and facilitate the recruitment of MYC to chromatin (<xref ref-type="bibr" rid="bib52">Thomas et al., 2015b</xref>). This is consistent with our findings that WBM site mutants of WDR5 are unable to rescue the growth defect caused by WDR5 loss. Notably, the association of MYC to its target genes is disrupted when the WBM site is mutated (<xref ref-type="bibr" rid="bib52">Thomas et al., 2015b</xref>).</p><p>A recently published study implicates WDR5 in maintaining metastatic outgrowth via trimethylation of H3K4 on the promoters of specific target genes including <italic>TGFB1</italic>, which enhances epithelial to mesenchymal transition (EMT) (<xref ref-type="bibr" rid="bib47">Punzi et al., 2019</xref>). Alternatively, by using a genome-wide approach and multiple TNBC cell line models, we did not observe alterations in EMT, which may be context specific. Conversely, we demonstrated a conserved and broad role for WDR5 in controlling RP gene expression (including <italic>RPL32</italic>, <italic>RPL34</italic>, <italic>RPS14</italic>, and <italic>RPS6</italic>) in a manner that is independent of KMT2 and H3K4me3 regulation at the promoters of RP genes. Therefore, the primary role of WDR5 may be to regulate proteostasis in TNBC cells. As aberrant protein translation affects multiple features of malignant cells, targeting WDR5 would be effective in treating both early or late stages of breast cancer (<xref ref-type="bibr" rid="bib27">Grzmil and Hemmings, 2012</xref>). Consistent with this idea, knockdown of WDR5 independently decreases primary tumor growth and lung metastasis in vivo. Moreover, different RP genes and ribosomes may have specialized cellular functions (<xref ref-type="bibr" rid="bib8">Barna et al., 2022</xref>). In fact, WDR5 knockdown also induces expression of several RP genes (including <italic>RPL14</italic>, <italic>RPL21</italic>, <italic>RPS13</italic>, and <italic>RPS27</italic>), which could have opposite roles as the RP genes down-regulated by WDR5 knockdown. Future studies will be needed to elucidate how WDR5-dependent protein translation contributes to the different steps of breast cancer progression, dissemination, and colonization.</p><p>The regulation of proteostasis and targeting protein translation in particular are potential therapeutic vulnerabilities of cancer cells. Interestingly, we demonstrated that the regulation of RP gene expression and protein translation could be inhibited by using the WDR5 inhibitor OICR-9429 or WDR5 degrader MS67, consistent with our genetic approach with WDR5 gene knockdown. Proteolysis-targeting chimeras (PROTACs) are hetero-bifunctional small molecules that can recruit desired target proteins to the E3 ubiquitin ligase complex for proteasomal degradation (<xref ref-type="bibr" rid="bib44">Paiva and Crews, 2019</xref>). Multiple PROTAC degraders have entered clinical trials for cancer treatment (<xref ref-type="bibr" rid="bib31">He et al., 2020</xref>). Here, we leveraged the newly designed WDR5 degrader to test its efficacy in WDR5 degradation in breast cancer cells. In fact, the WDR5 degrader MS67 showed more potent effects as compared to the WDR5 inhibitor OICR-9429. MS67 led to WDR5 degradation within 4 hr and is reversible after withdrawal of drug treatment (<xref ref-type="bibr" rid="bib56">Yu et al., 2021</xref>), allowing for temporal control of WDR5 targeting. Unlike small molecule inhibitors, PROTAC molecules can be reused within the cells, which would lower the required concentration for drug treatment. Additionally, PROTAC is able to degrade the entire protein in the cells, which could overcome some potential drug resistant mechanisms. Our results thus suggest that WDR5 degradation is a potential therapeutic strategy to inhibit metastatic progression in breast cancer.</p><p>Finally, we discovered that multiple mTOR inhibitors can act synergistically with WDR5 targeting. In addition, we show that the second-generation mTOR inhibitor, OSI-027, which targets both mTORC1 and mTORC2, works better than first-generation inhibitor, everolimus, when treated in combination with WDR5 targeting. Both mTOR inhibition or WDR5 degradation can inhibit translation but through different mechanisms. mTOR integrates survival signals with protein synthesis. As translation initiation is initially repressed upon mTOR inhibition, negative feedback loops can cause aberrant stimulation of upstream signaling via AKT activation, which may diminish the effect of mTOR inhibitors (<xref ref-type="bibr" rid="bib49">Rozengurt et al., 2014</xref>; <xref ref-type="bibr" rid="bib60">Zou et al., 2020</xref>). We also observed up-regulation of RP gene expression after mTOR inhibitor treatment, suggesting that epigenetic activation of ribosomal genes may be another compensatory response to mTOR inhibition. Importantly, we demonstrated that WDR5 inhibition is able to counteract this feedback activation of RP genes. Altogether, our study provides molecular and cell biological evidence that WDR5 is an important epigenetic mediator of protein translation and that this distinct function of WDR5 may be leveraged for treatment of TNBC.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Flag (mouse monoclonal)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">F1804</td><td align="left" valign="bottom">IP (1:50), WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-vinculin (mouse monoclonal)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">V9131</td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-tubulin (mouse monoclonal)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">T5168</td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-WDR5 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#13105</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-RBBP5 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#13171</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-KMT2A/MLL1-C (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#14197</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CXXC1 (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#12585</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-HCFC1 (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#69690</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-WDR82 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#99715</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho p70S6K (Thr389) (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#9202</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho 4E-BP1 (Thr37/46) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#2855</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-4E-BP1 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#9644</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-cleaved caspase 3 (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#9661</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-DPY30 (rabbit polyclonal)</td><td align="left" valign="bottom">Bethyl Laboratories</td><td align="left" valign="bottom">A304-296A</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho S6 (Ser240/244) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#5364</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-S6 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#2217</td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-M2 Flag (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#14793</td><td align="left" valign="bottom">Chromatin immunoprecipitation (ChIP) (10 µL)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-H3K4me3 (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Ab8580</td><td align="left" valign="bottom">ChIP (10 µg)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pINDUCER-10 (plasmid)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib40">Meerbrey et al., 2011</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Inducible shRNA knockdown with red fluorescent protein reporter</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pINDUCER-10-Blasticidin (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Version of pINDUCER-10 with blasticidin selection marker</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">p3XFlag-CMV-14-WDR5</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">#59974</td><td align="left" valign="bottom">WDR5 plasmid used for subcloning</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pDONR-211</td><td align="left" valign="bottom">ThermoFisher Scientific</td><td align="left" valign="bottom">#12536017</td><td align="left" valign="bottom">Used for cloning WDR5 into expression plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLenti-PSK-hygro-DEST</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">#19066</td><td align="left" valign="bottom">Used for cloning WDR5 into expression plasmid</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">MDA-MB-231</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-26</td><td align="left" valign="bottom">MDA-MB-231 expressing Luciferase</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">MDA-MB-231-LM2</td><td align="left" valign="bottom">Joan Massagué lab, Memorial Sloan Kettering Cancer Center</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lung metastatic derivative of MDA-MB-231</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">MDA-MB-231-BoM</td><td align="left" valign="bottom">Joan Massagué lab, Memorial Sloan Kettering Cancer Center</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Bone metastatic derivative of MDA-MB-231</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">MDA-MB-231-BrM3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Brain metastatic derivative of MDA-MB-231</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HCC1143</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-2321</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">MDA-MB-453</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-131</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">MCF7</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-22</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">T47D</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-133</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">MDA-MB-361</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-27</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">UACC893</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-1902</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">BT474</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-20</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">SKBR3</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-30</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="char" char="." valign="bottom">4T1</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-2539</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Puromycin</td><td align="left" valign="bottom">ThermoFischer Scientific</td><td align="left" valign="bottom">A1113802</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Blasticidin</td><td align="left" valign="bottom">ThermoFischer Scientific</td><td align="left" valign="bottom">A1113902</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Doxycycline</td><td align="left" valign="bottom">ThermoFischer Scientific</td><td align="left" valign="bottom">#446060050</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">MS67</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib56">Yu et al., 2021</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">WDR5 degrader</td></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">MS67N</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib56">Yu et al., 2021</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">WDR5 degrader control</td></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">OICR-9429</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">SML1209</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">OSI-027</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">#17379</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Everolimus</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">#11597</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Temsirolimus</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">#11590</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithm</td><td align="left" valign="bottom">R studio</td><td align="left" valign="bottom">R studio</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_000432">SCR_000432</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithm</td><td align="left" valign="bottom">STAR</td><td align="left" valign="bottom">STAR</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_004463">SCR_004463</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithm</td><td align="left" valign="bottom">GENCODEv96</td><td align="left" valign="bottom">GENCODEv96</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014966">SCR_014966</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithm</td><td align="left" valign="bottom">PyMol</td><td align="left" valign="bottom">PyMol</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_000305">SCR_000305</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay and kit</td><td align="left" valign="bottom">Cell proliferation reagent WST-1</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">#11644807001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay and kit</td><td align="left" valign="bottom">TruSeq Stranded mRNA Library Prep</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom">#20020594</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay and kit</td><td align="left" valign="bottom">High-capacity cDNA Reverse Transcription Kit</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">#4368813</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay and kit</td><td align="left" valign="bottom">Click-iT Cell Reaction Buffer Kit</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">C10269</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Antibodies and chemicals</title><p>For Co-IP and western blots, the following antibodies were obtained commercially: mouse anti-Flag (M2, F1804), mouse anti-vinculin (V9131), and mouse anti-tubulin (T5168) (Sigma, St. Louis, MO); rabbit anti-WDR5 (#13105), rabbit anti-RBBP5 (#13171), rabbit anti-KMT2A/MLL1-C (#14197), rabbit anti-CXXC1(#12585), rabbit anti-HCFC1 (#69690), rabbit anti-WDR82 (#99715), rabbit anti-phospho p70 S6K (Thr389) (#9205), rabbit anti-p70 S6K (#9202), rabbit anti-phospho 4E-BP1 (Thr37/46) (#2855), rabbit anti-4E-BP1 (#9644), and anti-cleaved caspase 3 (#9661) (Cell Signaling Technology, Danvers, MA, USA); rabbit anti-DPY30 (A304-96A) (Bethyl Laboratories, Montgomery, TX, USA).</p><p>For drug treatment experiments, WDR5 inhibitor OICR-9429 (Sigma, SML1209 and Cayman Chemical, #16095) and control OICR-0547 (Structural Genomics Consortium), and mTOR inhibitors, OSI-027 (Cayman Chemical, #17379), everolimus (Cayman Chemical, #11597), and temsirolimus (Cayman Chemical, #11590) were used. Compounds of WDR5 degrader MS67 and negative control MS67N were synthesized in Jian Jin’s lab.</p></sec><sec id="s4-2"><title>Plasmids and virus generation</title><p>Frozen bacterial stocks harboring the shRNA library were generated by the Westbrook lab. pGIPZ plasmid harboring hairpins and barcodes were digested with Xho I and Mlu I and subcloned into the pINDUCER10 plasmid. The list of hairpin sequences and shRNA knockdown efficiency is available in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>. For cloning of the WDR5 mutants, BP (atttB x attP) cloning primers were designed against p3XFlag-CMV-14-WDR5. Two-step PCR was performed to generate shRNA resistant mutant WDR5. Briefly, two sets of primers were designed such that they overlap at the site of mutagenesis. The product from the PCR was then used for BP (Thermo Fisher, # 11789020) or LR (attL x attR, Thermo Fisher, #11791020) reaction into pDONR-211 or pLenti-PSK-hygro-DEST. p3XFlag-CMV-14-WDR5 was a gift from Debu Chakravarti (Addgene, #59974). A list of cloning oligos is available in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>.</p><p>For virus generation, HEK293T cells were transfected with 1.2 µg each of VSV-G, TAT, RAII, and HyPM packaging plasmids along with 11.2 µg of lentiviral plasmid. OptiMEM and TransIT-293 Transfection Reagent (Mirus, MIR2700) were used following manufacturer protocol. Viruses were collected at 48 hr and 72 hr and filtered through a 0.45 μm filter.</p></sec><sec id="s4-3"><title>Cell culture and stable cell lines generation</title><p>MDA-MB-231 and its metastatic derivatives, MDA-MB-231-LM2 (LM2), MDA-MB-231-BoM (BoM) and MDA-MB-231-BrM3 (BrM3) breast cancer cells and HEK293T cells were cultured in Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine serum and 100 U/mL penicillin and 100 µg/mL streptomycin. LM2 and BoM have been previously described and were obtained from J. Massagué (Memorial Sloan Kettering Cancer Center, New York) (<xref ref-type="bibr" rid="bib41">Minn et al., 2005</xref>; <xref ref-type="bibr" rid="bib34">Kang et al., 2003</xref>). BrM3 is a metastatic derivative generated by subjecting MDA-MB-231-BrM2 cells to one round of in vivo selection (<xref ref-type="bibr" rid="bib12">Bos et al., 2009</xref>). HCC1143, MDA-MB-453, MCF7, T47D, MDA-MB-361, UACC893, BT474, SKBR3, and 4T1 breast cancer cells were cultured in RPMI1640 supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin. Cells were periodically tested for mycoplasma contamination and were negative, and they were authenticated using short tandem repeat profiling with GenePrint 10 system (Promega, #B9510).</p><p>For generation of cell lines, viruses harboring pINDUCER10-puromycin or pINDUCER10-blasticidin constructs were titrated using the target cell lines. Cells were infected at an multiplicity of infection of 1 and selected using either 0.8 µg/mL puromycin or 10 µg/mL blasticidin. For generation of cell lines harboring WDR5 mutants, optimal viral dose was determined empirically by western blot visualization to assess equal expression of WDR5 across mutant cell lines. LM2 cells with re-introduction of WDR5 mutants were selected with 800 µg/mL hygromycin.</p></sec><sec id="s4-4"><title>Minipool generation for in vitro and in vivo screening</title><p>Minipools were created by equally mixing 8–10 individual LM2 cell lines harboring pINDUCER10 hairpins targeting each epigenetic modifier together with two LM2 positive control cell lines (shBUD31 and shSAE2) and two negative control cell lines (shCHEK1 and shSTAMBP). For in vitro screening, minipool cells were plated into 10 cm dishes with or without 1 μg/mL of DOX. A portion of minipool cells were collected as day 0 samples as the controls. Every 2 days, the cells were pelleted, and all samples were proceeded to gDNA isolation and gDNA qPCR. For in vivo screening, 5×10<sup>5</sup> minipool cells were injected into nude mice through tail vein. Lung metastases were monitored weekly with in vivo live imaging. At the end point, the mice were sacrificed, and the lung tissue was harvested for gDNA isolation and gDNA qPCR. For the screening readout analyses, all qPCR results were normalized to the value from day 0. The fold change was obtained from +DOX/−DOX for both in vitro and in vivo screen. A table of complete results of both in vivo and in vitro screens is available in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>.</p></sec><sec id="s4-5"><title>Animal studies</title><p>Female athymic Nude-<italic>Foxn1<sup>nu</sup></italic> immunodeficient (6–8 weeks old) mice (Envigo) were used for lung-metastasis experiments with human cell lines. For in vivo screening, 5×10<sup>5</sup> cells were injected via tail vein in 0.1 mL saline. For WDR5 in vivo validation experiment, cells were treated with DOX for 3 days prior to injection, and 2×10<sup>5</sup> cells were injected via tail vein in 0.1 mL saline. Mice were placed on DOX chow (Envigo, TD.01306) 5 days prior to injection. All the in vivo metastasis signals, including lung metastasis and whole-body metastasis, were monitored by weekly bioluminescence imaging with an IVIS system coupled to Living Image acquisition and analysis software (Xenogen). Luminescence signals were quantified at the indicated time points as previously described. Values of luminescence photon flux of each time point were normalized to the value obtained immediately after xenografting (day 0).</p><p>For mammary fat pad tumor assays, control and shWDR5-1 LM2 cells (1×10<sup>6</sup>) were resuspended in 0.1 mL of saline and matrigel (Corning, #356231) mix and then injected into mammary fat pad (the fourth mammary glands) of non-obese diabetic-severe combined immunodeficiency (NOD-SCID) mice (6 weeks old). Tumor were monitored every 7 days by measuring the tumor length (L) and width (W). Tumor volume was calculated as V=L×W<sup>2</sup>/2. Mice were euthanized when primary tumors reached 1000 mm<sup>3</sup>. All animal procedures have been approved by the Institutional Animal Care and Use Committee of Yale University under animal protocol 2021–11286.</p></sec><sec id="s4-6"><title>Lung tissue harvest and gDNA isolation</title><p>Mice were sacrificed and whole body perfused with 10 mL of PBS. For gDNA isolation, the harvested lungs were placed into a microcentrifuge tube and snap frozen with liquid nitrogen. The frozen tissues were then placed into an aluminum block on dry ice. Each tube of the lung tissue was allowed to thaw enough for further mincing with surgical scissors and then refrozen by dipping them in liquid nitrogen bath. This process was repeated two to three times until no visible tissue chunk was observed. 60 mg of homogenized tissue was then aliquoted out and processed with the QIAmp DNA mini kit (Qiagen 51304) following manufacturer’s protocols.</p></sec><sec id="s4-7"><title>Western blot and Co-IP</title><p>Cells were lysed in 1× high salt lysis buffer (50 mM Tris-HCl pH 8, 320 mM NaCl, 0.1 mM EDTA, 0.5% NP-40, and 10% glycerol) or [radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate (SDS)) supplemented with 1× protease inhibitor (Roche cOmplete 11836153001). Cell lysates were vortexed and centrifuged, and the supernatants were subjected to protein quantification by Bradford reagent (Bio-Rad 5000006) and sample preparation by sample buffer (10% glycerol, 50 mM Tris-HCl [pH 6.8], 2% SDS, 0.01% bromophenol blue, and 8% β-mercaptoethanol). Protein samples were resolved by SDS-PAGE according to the standard protocol and transferred onto 0.45 μm nitrocellulose membranes (Bio-Rad 1620115) and blotted with the primary and secondary antibodies as described.</p><p>For Co-IP experiments, cells were lysed with RIPA buffer. The prepared protein extracts were precleared with protein A/G beads (Pierce, #20421) for 1 hr at 4°C then incubated with anti-Flag M2 affinity gel for 2 hr for Co-IP, followed by western blot analysis.</p></sec><sec id="s4-8"><title>Colony formation assays and WST-1 cell proliferation assays</title><p>Colony formation assays were done by seeding single cells in 6 or 12 well plates. Media was replenished every 3 days with indicated treatments. Colonies were fixed in 4% para-formaldehyde (PFA), followed by 0.5% crystal violet staining for 30 min at room temperature and rinsed with water. Quantification was performed using the ImageJ software plugin ColonyArea. Statistical significance was determined using unpaired, two-tailed Student’s <italic>t</italic> test performed on intensity values from ColonyArea. For WST-1 cell proliferation assays (#11644807001, Roche), cells were seeded in 96 well plate for indicated days growth and then were assayed according to the manufacturer’s instructions.</p></sec><sec id="s4-9"><title>RNA-sequencing</title><p>Cells from knockdown control or shWDR5-1 group were harvested with QIAzol Lysis Reagent (Qiagen) and homogenized using QIAshredder tubes (Qiagen). For each cell line, shRNA expression was induced with DOX (1 μg/mL) for 3 days, and three biological replicates were harvested at different passages. RNA isolation was performed using miRNeasy with on-column DNase digestion. External RNA controls consortium spike-in RNA was added in proportion to the number of cells obtained during cell counts. Library generation was performed using TruSeq stranded mRNA library prep kit (Illumina). Paired-end sequencing was performed using an Illumina HiSeq4000 sequencer, generating an average of 59 million reads per library. Reads were aligned to hg38, and gene counts to GENCODEv96 transcripts were obtained using STAR aligner v2.7.0 with default parameters. The hg38 and GENCODEv96 annotations were appended to include the ERCC sequences. DESeq2 was used to obtain differential gene expression, and HTSFilter was used to filter for expressed genes. Significant differences were identified using a Benjamini-Hochberg adjusted p-value cut-off of 0.05. RNA-seq data have been deposited into the National Center for Biotechnology Information Gene Expression Omnibus database under GSE196666.</p></sec><sec id="s4-10"><title>RT-qPCR and barcode qPCR</title><p>Total RNA was extracted using the RNeasy Plus Mini Kit (Qiagen 74136), and reverse transcription was performed using High-capacity cDNA Reverse Transcription kit (ThermoFisher 4385614). The resulting cDNA was diluted with water, and Fast SYBR Green Master Mix (ThermoFisher 4385614) was used for real-time PCR. <italic>GAPDH</italic> was utilized as loading controls. Samples were run in quadruplicate, and the experiments were performed at least three times. Primer sequences are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1f</xref>.</p><p>For barcode qPCR, barcode primers were designed to amplify only 1 barcode sequence among the 89 unique barcodes in the entire library. The primer set targeting the tetracycline response element (TRE) element in pINDUCER10 was used for normalization. The full list of barcode qPCR primers used for detection of hairpin abundance is available in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1g</xref>.</p></sec><sec id="s4-11"><title>Translation rate assay</title><p>Cells were starved of L-methionine for 30 min and subsequently incubated with 50 μM homopropargylglycine (HPG; Life Technologies #C10186) for 1–4 hr in treatment media. Cells were then trypsinized and fixed in 4% PFA. A Click-IT kit (Life Technologies #C10269) used to label HPG. Labeled cells were analyzed using an Cytoflex flow cytometer. Translation rates were determined based on the slope of HPG incorporation over time. Significance determined using one sample <italic>t</italic> test to compare each treatment value to the hypothetical value 1 for the DMSO control.</p></sec><sec id="s4-12"><title>Chromatin immunoprecipitation qPCR</title><p>Cells growth in 15 cm dishes were washed with PBS and cross-linked with 1% formaldehyde in DMEM media for 10 min and quenched with 0.125 M glycine for 5 min. Cells were washed with cold PBS and scraped and pooled. Following washes, cell pellets were lysed in sonication buffer (20 mM Tris pH 8.0, 2 mM EDTA, 0.5 mM EGTA, 1× protease inhibitor, 0.5% SDS, and 0.5 mM phenylmethanesulfonyl fluoride (PMSF)) at a concentration of 3 mL per 1×10<sup>8</sup> cells for 10 min. Sonication was performed using the Qsonica Q800R sonicator (Qsonica) set to 70% amplitude, 15 s on and 45 s off for a total of 30 min on. Sonicated materials were precleared with 50% protein A agarose (ThermoFisher 20421). Antibodies were added into precleared material and rotated overnight at 4°C. 50% protein A slurry was then added, and the tubes were rotated at 4°C for 2 hr. In order to reverse crosslinks and purify DNA, NaCl was added to elute ChIP material and incubated overnight at 65°C and then digested with proteinase K. Glycotube (ThermoFisher AM9515) was added as co-precipitant and phenol-chloroform isolation, and ethanol precipitation was performed to isolate ChIP DNA. All sample DNA pellets were resuspended in 200 μL of water. 2 μL of DNA was used for each qPCR reaction, and reactions were performed in quadruplicate.</p></sec><sec id="s4-13"><title>3D protein visualization</title><p>Protein crystal structure 2H14 (apo-WDR5) was downloaded from the Protein Data Bank and visualized using PyMol (The PyMOL Molecular Graphics System, Version 2.0 Schrdinger, LLC).</p></sec><sec id="s4-14"><title>Analysis of in vitro drug interaction</title><p>We employed coefficient of drug interaction to determine cytotoxicity. The coefficient of drug interaction (CDI) is calculated as follows: CDI = AB/(A×B). According to the colony formation intensity or translation rates of each group, AB is the ratio of the combination group to the control group; A or B is the ratio of the single agent group to the control group. Thus, CDI value &lt;1, =1, or &gt;1 indicates that the drugs are synergistic, additive, or antagonistic, respectively. A CDI &lt;0.7 indicates a significant synergistic effect (<xref ref-type="bibr" rid="bib43">Otahal et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Zhao et al., 2014</xref>).</p></sec><sec id="s4-15"><title>Statistical analysis</title><p>Comparisons between two groups were performed using an unpaired two-side Student’s <italic>t</italic> test unless indicated otherwise. Graphs represent either group mean values ± SEM or individual values (as indicated in the figure legends). For animal experiments, each tumor graft was an independent sample. All experiments were reproduced at least three times.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc, Cullgen, Inc and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc and a consultant for Cullgen, Inc, EpiCypher, Inc and Accent Therapeutics, Inc</p></fn><fn fn-type="COI-statement" id="conf4"><p>has received research funding un-related to this study from AstraZeneca Inc</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Investigation</p></fn><fn fn-type="con" id="con11"><p>Investigation</p></fn><fn fn-type="con" id="con12"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con13"><p>Investigation</p></fn><fn fn-type="con" id="con14"><p>Resources</p></fn><fn fn-type="con" id="con15"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con16"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con17"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal procedures have been approved by the Institutional Animal Care and Use Committee of Yale University under animal protocol 2021-11286.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Information related to shRNA characterization, in vivo and in vitro screening, RNA-seq analysis, cloning oligos and primers.</title><p>(a) List of hairpin sequences and knockdown efficiency.</p><p>(b) Results of in vivo and in vitro screen. l2fc, Log2 fold change</p><p>(c) Shared differentially expressed genes (DEGs) after WDR5 knockdown in LM2, BrM3, and BoM. l2fc, Log2 fold change; padj, adjusted p value.</p><p>(d) Enriched pathways of differentially expressed genes (DEGs) after WDR5 knockdown in LM2, BrM3, BoM, or all three cell lines (common). Enriched pathways, significance, combined score, and overlapping genes are shown.</p><p>(e) List of cloning oligos.</p><p>(f) List of primers used for RT-qPCR.</p><p>(g) List of barcode qPCR primers.</p></caption><media xlink:href="elife-78163-supp1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-78163-transrepform1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>RNA-seq data have been deposited into the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus database under GSE196666.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>WL</given-names></name><name><surname>Chen</surname><given-names>JF</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE196666">GSE196666</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We would like to thank all members of Yan, Nguyen, and Stern laboratories at Yale University for helpful discussions, Dr. Mei Zhong at Yale Stem Cell Center Genomics Core facility for helping with sample preparation for RNA-seq, Dr. Joan Massagué at Memorial Sloan Kettering Cancer Center for providing MDA-MB-231, LM2, and BoM cells, Dr. Yibin Kang at Princeton University for providing BrM2 cells, Dr. Narendra Wajapeyee at the University of Alabama Birmingham for helping with compiling the epigenetic gene list. Sequencing done at Yale Stem Cell Center Genomics Core facility was supported by the Connecticut Regenerative Medicine Research Fund and the Li Ka Shing Foundation. Figure panels 1 A, 4B, 5 A, and Figure 1—figure supplement 1A were created with <ext-link ext-link-type="uri" xlink:href="http://www.BioRender.com">BioRender.com</ext-link>. The control drug OICR-0547 was supplied by the Structural Genomics Consortium under an Open Science Trust Agreement: <ext-link ext-link-type="uri" xlink:href="http://www.thesgc.org/click-trust">http://www.thesgc.org/click-trust</ext-link>.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aho</surname><given-names>ER</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Gogliotti</surname><given-names>RD</given-names></name><name><surname>Howard</surname><given-names>GC</given-names></name><name><surname>Phan</surname><given-names>J</given-names></name><name><surname>Acharya</surname><given-names>P</given-names></name><name><surname>Macdonald</surname><given-names>JD</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Lorey</surname><given-names>SL</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Wenzel</surname><given-names>S</given-names></name><name><surname>Foshage</surname><given-names>AM</given-names></name><name><surname>Alvarado</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Shaw</surname><given-names>JG</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Weissmiller</surname><given-names>AM</given-names></name><name><surname>Thomas</surname><given-names>LR</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name><name><surname>Hall</surname><given-names>MD</given-names></name><name><surname>Hiebert</surname><given-names>SW</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Stauffer</surname><given-names>SR</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Displacement of WDR5 from chromatin by a WIN site inhibitor with picomolar affinity</article-title><source>Cell Reports</source><volume>26</volume><fpage>2916</fpage><lpage>2928</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.02.047</pub-id><pub-id pub-id-type="pmid">30865883</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahuja</surname><given-names>N</given-names></name><name><surname>Sharma</surname><given-names>AR</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Epigenetic therapeutics: A new weapon in the war against cancer</article-title><source>Annual Review of Medicine</source><volume>67</volume><fpage>73</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-111314-035900</pub-id><pub-id pub-id-type="pmid">26768237</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Mahmood</surname><given-names>S</given-names></name><name><surname>Sapiezynski</surname><given-names>J</given-names></name><name><surname>Garbuzenko</surname><given-names>OB</given-names></name><name><surname>Minko</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Metastatic and triple-negative breast cancer: challenges and treatment options</article-title><source>Drug Delivery and Translational Research</source><volume>8</volume><fpage>1483</fpage><lpage>1507</lpage><pub-id pub-id-type="doi">10.1007/s13346-018-0551-3</pub-id><pub-id pub-id-type="pmid">29978332</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ang</surname><given-names>YS</given-names></name><name><surname>Tsai</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>DF</given-names></name><name><surname>Monk</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Ratnakumar</surname><given-names>K</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Darr</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Rendl</surname><given-names>M</given-names></name><name><surname>Bernstein</surname><given-names>E</given-names></name><name><surname>Schaniel</surname><given-names>C</given-names></name><name><surname>Lemischka</surname><given-names>IR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Wdr5 mediates self-renewal and reprogramming via the embryonic stem cell core transcriptional network</article-title><source>Cell</source><volume>145</volume><fpage>183</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.03.003</pub-id><pub-id pub-id-type="pmid">21477851</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonova</surname><given-names>A</given-names></name><name><surname>Hummel</surname><given-names>B</given-names></name><name><surname>Khavaran</surname><given-names>A</given-names></name><name><surname>Redhaber</surname><given-names>DM</given-names></name><name><surname>Aprile-Garcia</surname><given-names>F</given-names></name><name><surname>Rawat</surname><given-names>P</given-names></name><name><surname>Gundel</surname><given-names>K</given-names></name><name><surname>Schneck</surname><given-names>M</given-names></name><name><surname>Hansen</surname><given-names>EC</given-names></name><name><surname>Mitschke</surname><given-names>J</given-names></name><name><surname>Mittler</surname><given-names>G</given-names></name><name><surname>Miething</surname><given-names>C</given-names></name><name><surname>Sawarkar</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Heat-shock protein 90 controls the expression of cell-cycle genes by stabilizing metazoan-specific host-cell factor HCFC1</article-title><source>Cell Reports</source><volume>29</volume><fpage>1645</fpage><lpage>1659</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.09.084</pub-id><pub-id pub-id-type="pmid">31693902</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>N</given-names></name><name><surname>Ryder</surname><given-names>S</given-names></name><name><surname>Forbes</surname><given-names>C</given-names></name><name><surname>Ross</surname><given-names>J</given-names></name><name><surname>Quek</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A systematic review of the international prevalence of <italic>BRCA</italic> mutation in breast cancer</article-title><source>Clinical Epidemiology</source><volume>11</volume><fpage>543</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.2147/CLEP.S206949</pub-id><pub-id pub-id-type="pmid">31372057</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Jamiyandorj</surname><given-names>U</given-names></name><name><surname>Kim</surname><given-names>KM</given-names></name><name><surname>Noh</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>JR</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Kwon</surname><given-names>KS</given-names></name><name><surname>Jung</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>BH</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Moon</surname><given-names>WS</given-names></name><name><surname>Sylvester</surname><given-names>KG</given-names></name><name><surname>Jang</surname><given-names>KY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CK2α/CSNK2A1 phosphorylates SIRT6 and is involved in the progression of breast carcinoma and predicts shorter survival of diagnosed patients</article-title><source>The American Journal of Pathology</source><volume>186</volume><fpage>3297</fpage><lpage>3315</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2016.08.007</pub-id><pub-id pub-id-type="pmid">27746184</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barna</surname><given-names>M</given-names></name><name><surname>Karbstein</surname><given-names>K</given-names></name><name><surname>Tollervey</surname><given-names>D</given-names></name><name><surname>Ruggero</surname><given-names>D</given-names></name><name><surname>Brar</surname><given-names>G</given-names></name><name><surname>Greer</surname><given-names>EL</given-names></name><name><surname>Dinman</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The promises and pitfalls of specialized ribosomes</article-title><source>Molecular Cell</source><volume>82</volume><fpage>2179</fpage><lpage>2184</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2022.05.035</pub-id><pub-id pub-id-type="pmid">35714581</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Campone</surname><given-names>M</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name><name><surname>Burris</surname><given-names>HA</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name><name><surname>Sahmoud</surname><given-names>T</given-names></name><name><surname>Noguchi</surname><given-names>S</given-names></name><name><surname>Gnant</surname><given-names>M</given-names></name><name><surname>Pritchard</surname><given-names>KI</given-names></name><name><surname>Lebrun</surname><given-names>F</given-names></name><name><surname>Beck</surname><given-names>JT</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Yardley</surname><given-names>D</given-names></name><name><surname>Deleu</surname><given-names>I</given-names></name><name><surname>Perez</surname><given-names>A</given-names></name><name><surname>Bachelot</surname><given-names>T</given-names></name><name><surname>Vittori</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Mukhopadhyay</surname><given-names>P</given-names></name><name><surname>Lebwohl</surname><given-names>D</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer</article-title><source>The New England Journal of Medicine</source><volume>366</volume><fpage>520</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1109653</pub-id><pub-id pub-id-type="pmid">22149876</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>M</given-names></name><name><surname>Robichaud</surname><given-names>N</given-names></name><name><surname>Hulea</surname><given-names>L</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name><name><surname>Pelletier</surname><given-names>J</given-names></name><name><surname>Topisirovic</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Targeting the translation machinery in cancer</article-title><source>Nature Reviews. Drug Discovery</source><volume>14</volume><fpage>261</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/nrd4505</pub-id><pub-id pub-id-type="pmid">25743081</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>LP</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Epigenetic mechanisms in commonly occurring cancers</article-title><source>DNA and Cell Biology</source><volume>31 Suppl 1</volume><fpage>S49</fpage><lpage>S61</lpage><pub-id pub-id-type="doi">10.1089/dna.2012.1654</pub-id><pub-id pub-id-type="pmid">22519822</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bos</surname><given-names>PD</given-names></name><name><surname>Zhang</surname><given-names>XHF</given-names></name><name><surname>Nadal</surname><given-names>C</given-names></name><name><surname>Shu</surname><given-names>W</given-names></name><name><surname>Gomis</surname><given-names>RR</given-names></name><name><surname>Nguyen</surname><given-names>DX</given-names></name><name><surname>Minn</surname><given-names>AJ</given-names></name><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>Gerald</surname><given-names>WL</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name><name><surname>Massagué</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Genes that mediate breast cancer metastasis to the brain</article-title><source>Nature</source><volume>459</volume><fpage>1005</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1038/nature08021</pub-id><pub-id pub-id-type="pmid">19421193</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryan</surname><given-names>AF</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Howard</surname><given-names>GC</given-names></name><name><surname>Guarnaccia</surname><given-names>AD</given-names></name><name><surname>Woodley</surname><given-names>CM</given-names></name><name><surname>Aho</surname><given-names>ER</given-names></name><name><surname>Rellinger</surname><given-names>EJ</given-names></name><name><surname>Matlock</surname><given-names>BK</given-names></name><name><surname>Flaherty</surname><given-names>DK</given-names></name><name><surname>Lorey</surname><given-names>SL</given-names></name><name><surname>Chung</surname><given-names>DH</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Weissmiller</surname><given-names>AM</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>WDR5 is a conserved regulator of protein synthesis gene expression</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>2924</fpage><lpage>2941</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa051</pub-id><pub-id pub-id-type="pmid">31996893</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>WL</given-names></name><name><surname>Greer</surname><given-names>CB</given-names></name><name><surname>Chen</surname><given-names>JF</given-names></name><name><surname>Arnal-Estapé</surname><given-names>A</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name><name><surname>Nguyen</surname><given-names>DX</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Specific chromatin landscapes and transcription factors couple breast cancer subtype with metastatic relapse to lung or brain</article-title><source>BMC Medical Genomics</source><volume>13</volume><elocation-id>33</elocation-id><pub-id pub-id-type="doi">10.1186/s12920-020-0695-0</pub-id><pub-id pub-id-type="pmid">32143622</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Histone demethylases set the stage for cancer metastasis</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>e15</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2004188</pub-id><pub-id pub-id-type="pmid">23633674</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Cheung</surname><given-names>WKC</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>SY</given-names></name><name><surname>Chan</surname><given-names>SW</given-names></name><name><surname>Booth</surname><given-names>CJ</given-names></name><name><surname>Nguyen</surname><given-names>DX</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Histone demethylase RBP2 is critical for breast cancer progression and metastasis</article-title><source>Cell Reports</source><volume>6</volume><fpage>868</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.02.004</pub-id><pub-id pub-id-type="pmid">24582965</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carugo</surname><given-names>A</given-names></name><name><surname>Genovese</surname><given-names>G</given-names></name><name><surname>Seth</surname><given-names>S</given-names></name><name><surname>Nezi</surname><given-names>L</given-names></name><name><surname>Rose</surname><given-names>JL</given-names></name><name><surname>Bossi</surname><given-names>D</given-names></name><name><surname>Cicalese</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>PK</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Pettazzoni</surname><given-names>PF</given-names></name><name><surname>Akdemir</surname><given-names>KC</given-names></name><name><surname>Bristow</surname><given-names>CA</given-names></name><name><surname>Robinson</surname><given-names>FS</given-names></name><name><surname>Tepper</surname><given-names>J</given-names></name><name><surname>Sanchez</surname><given-names>N</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Estecio</surname><given-names>MR</given-names></name><name><surname>Giuliani</surname><given-names>V</given-names></name><name><surname>Dellino</surname><given-names>GI</given-names></name><name><surname>Riva</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>W</given-names></name><name><surname>Di Francesco</surname><given-names>ME</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>D’Alesio</surname><given-names>C</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Jones</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Fleming</surname><given-names>JB</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Pelicci</surname><given-names>PG</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name><name><surname>Lanfrancone</surname><given-names>L</given-names></name><name><surname>Heffernan</surname><given-names>TP</given-names></name><name><surname>Draetta</surname><given-names>GF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>In vivo functional platform targeting patient-derived xenografts identifies WDR5-myc association as a critical determinant of pancreatic cancer</article-title><source>Cell Reports</source><volume>16</volume><fpage>133</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.05.063</pub-id><pub-id pub-id-type="pmid">27320920</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Gu</surname><given-names>P</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Zhong</surname><given-names>G</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>8293</elocation-id><pub-id pub-id-type="doi">10.1038/srep08293</pub-id><pub-id pub-id-type="pmid">25656485</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JF</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The roles of epigenetics in cancer progression and metastasis</article-title><source>The Biochemical Journal</source><volume>478</volume><fpage>3373</fpage><lpage>3393</lpage><pub-id pub-id-type="doi">10.1042/BCJ20210084</pub-id><pub-id pub-id-type="pmid">34520519</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>CY</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Mullokandov</surname><given-names>G</given-names></name><name><surname>Bosch</surname><given-names>A</given-names></name><name><surname>Qadeer</surname><given-names>ZA</given-names></name><name><surname>Cihan</surname><given-names>E</given-names></name><name><surname>Rapp</surname><given-names>Z</given-names></name><name><surname>Parsons</surname><given-names>R</given-names></name><name><surname>Aguirre-Ghiso</surname><given-names>JA</given-names></name><name><surname>Farias</surname><given-names>EF</given-names></name><name><surname>Brown</surname><given-names>BD</given-names></name><name><surname>Gaspar-Maia</surname><given-names>A</given-names></name><name><surname>Bernstein</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cbx8 acts non-canonically with wdr5 to promote mammary tumorigenesis</article-title><source>Cell Reports</source><volume>16</volume><fpage>472</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.06.002</pub-id><pub-id pub-id-type="pmid">27346354</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Zhan</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>WDR5 expression is prognostic of breast cancer outcome</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0124964</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0124964</pub-id><pub-id pub-id-type="pmid">26355959</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dias</surname><given-names>J</given-names></name><name><surname>Van Nguyen</surname><given-names>N</given-names></name><name><surname>Georgiev</surname><given-names>P</given-names></name><name><surname>Gaub</surname><given-names>A</given-names></name><name><surname>Brettschneider</surname><given-names>J</given-names></name><name><surname>Cusack</surname><given-names>S</given-names></name><name><surname>Kadlec</surname><given-names>J</given-names></name><name><surname>Akhtar</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structural analysis of the KANSL1/WDR5/KANSL2 complex reveals that WDR5 is required for efficient assembly and chromatin targeting of the NSL complex</article-title><source>Genes &amp; Development</source><volume>28</volume><fpage>929</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1101/gad.240200.114</pub-id><pub-id pub-id-type="pmid">24788516</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebright</surname><given-names>RY</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Wittner</surname><given-names>BS</given-names></name><name><surname>Niederhoffer</surname><given-names>KL</given-names></name><name><surname>Nicholson</surname><given-names>BT</given-names></name><name><surname>Bardia</surname><given-names>A</given-names></name><name><surname>Truesdell</surname><given-names>S</given-names></name><name><surname>Wiley</surname><given-names>DF</given-names></name><name><surname>Wesley</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Mai</surname><given-names>A</given-names></name><name><surname>Aceto</surname><given-names>N</given-names></name><name><surname>Vincent-Jordan</surname><given-names>N</given-names></name><name><surname>Szabolcs</surname><given-names>A</given-names></name><name><surname>Chirn</surname><given-names>B</given-names></name><name><surname>Kreuzer</surname><given-names>J</given-names></name><name><surname>Comaills</surname><given-names>V</given-names></name><name><surname>Kalinich</surname><given-names>M</given-names></name><name><surname>Haas</surname><given-names>W</given-names></name><name><surname>Ting</surname><given-names>DT</given-names></name><name><surname>Toner</surname><given-names>M</given-names></name><name><surname>Vasudevan</surname><given-names>S</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name><name><surname>Maheswaran</surname><given-names>S</given-names></name><name><surname>Micalizzi</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis</article-title><source>Science</source><volume>367</volume><fpage>1468</fpage><lpage>1473</lpage><pub-id pub-id-type="doi">10.1126/science.aay0939</pub-id><pub-id pub-id-type="pmid">32029688</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>EJ</given-names></name><name><surname>Kawasawa</surname><given-names>YI</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Dovat</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>WDR5 high expression and its effect on tumorigenesis in leukemia</article-title><source>Oncotarget</source><volume>7</volume><fpage>37740</fpage><lpage>37754</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.9312</pub-id><pub-id pub-id-type="pmid">27192115</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Angulo</surname><given-names>AM</given-names></name><name><surname>Timms</surname><given-names>KM</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Litton</surname><given-names>JK</given-names></name><name><surname>Potter</surname><given-names>J</given-names></name><name><surname>Lanchbury</surname><given-names>JS</given-names></name><name><surname>Stemke-Hale</surname><given-names>K</given-names></name><name><surname>Hennessy</surname><given-names>BT</given-names></name><name><surname>Arun</surname><given-names>BK</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name><name><surname>Do</surname><given-names>KA</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer</article-title><source>Clinical Cancer Research</source><volume>17</volume><fpage>1082</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2560</pub-id><pub-id pub-id-type="pmid">21233401</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grebien</surname><given-names>F</given-names></name><name><surname>Vedadi</surname><given-names>M</given-names></name><name><surname>Getlik</surname><given-names>M</given-names></name><name><surname>Giambruno</surname><given-names>R</given-names></name><name><surname>Grover</surname><given-names>A</given-names></name><name><surname>Avellino</surname><given-names>R</given-names></name><name><surname>Skucha</surname><given-names>A</given-names></name><name><surname>Vittori</surname><given-names>S</given-names></name><name><surname>Kuznetsova</surname><given-names>E</given-names></name><name><surname>Smil</surname><given-names>D</given-names></name><name><surname>Barsyte-Lovejoy</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Poda</surname><given-names>G</given-names></name><name><surname>Schapira</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>A</given-names></name><name><surname>Senisterra</surname><given-names>G</given-names></name><name><surname>Stukalov</surname><given-names>A</given-names></name><name><surname>Huber</surname><given-names>KVM</given-names></name><name><surname>Schönegger</surname><given-names>A</given-names></name><name><surname>Marcellus</surname><given-names>R</given-names></name><name><surname>Bilban</surname><given-names>M</given-names></name><name><surname>Bock</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>PJ</given-names></name><name><surname>Zuber</surname><given-names>J</given-names></name><name><surname>Bennett</surname><given-names>KL</given-names></name><name><surname>Al-Awar</surname><given-names>R</given-names></name><name><surname>Delwel</surname><given-names>R</given-names></name><name><surname>Nerlov</surname><given-names>C</given-names></name><name><surname>Arrowsmith</surname><given-names>CH</given-names></name><name><surname>Superti-Furga</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pharmacological targeting of the wdr5-MLL interaction in C/EBPα N-terminal leukemia</article-title><source>Nature Chemical Biology</source><volume>11</volume><fpage>571</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1859</pub-id><pub-id pub-id-type="pmid">26167872</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grzmil</surname><given-names>M</given-names></name><name><surname>Hemmings</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Translation regulation as a therapeutic target in cancer</article-title><source>Cancer Research</source><volume>72</volume><fpage>3891</fpage><lpage>3900</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-0026</pub-id><pub-id pub-id-type="pmid">22850420</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guarnaccia</surname><given-names>A</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Moonlighting with WDR5: A cellular multitasker</article-title><source>Journal of Clinical Medicine</source><volume>7</volume><elocation-id>E21</elocation-id><pub-id pub-id-type="doi">10.3390/jcm7020021</pub-id><pub-id pub-id-type="pmid">29385767</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guarnaccia</surname><given-names>AD</given-names></name><name><surname>Rose</surname><given-names>KL</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Popay</surname><given-names>TM</given-names></name><name><surname>Wang</surname><given-names>CE</given-names></name><name><surname>Guerrazzi</surname><given-names>K</given-names></name><name><surname>Hill</surname><given-names>S</given-names></name><name><surname>Woodley</surname><given-names>CM</given-names></name><name><surname>Hansen</surname><given-names>TJ</given-names></name><name><surname>Lorey</surname><given-names>SL</given-names></name><name><surname>Shaw</surname><given-names>JG</given-names></name><name><surname>Payne</surname><given-names>WG</given-names></name><name><surname>Weissmiller</surname><given-names>AM</given-names></name><name><surname>Olejniczak</surname><given-names>ET</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Impact of WIN site inhibitor on the WDR5 interactome</article-title><source>Cell Reports</source><volume>34</volume><elocation-id>108636</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108636</pub-id><pub-id pub-id-type="pmid">33472061</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harbeck</surname><given-names>N</given-names></name><name><surname>Penault-Llorca</surname><given-names>F</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Gnant</surname><given-names>M</given-names></name><name><surname>Houssami</surname><given-names>N</given-names></name><name><surname>Poortmans</surname><given-names>P</given-names></name><name><surname>Ruddy</surname><given-names>K</given-names></name><name><surname>Tsang</surname><given-names>J</given-names></name><name><surname>Cardoso</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Breast cancer</article-title><source>Nature Reviews. Disease Primers</source><volume>5</volume><elocation-id>66</elocation-id><pub-id pub-id-type="doi">10.1038/s41572-019-0111-2</pub-id><pub-id pub-id-type="pmid">31548545</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Huo</surname><given-names>Z</given-names></name><name><surname>Lv</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Hromas</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Proteolysis targeting chimeras (protacs) are emerging therapeutics for hematologic malignancies</article-title><source>Journal of Hematology &amp; Oncology</source><volume>13</volume><elocation-id>103</elocation-id><pub-id pub-id-type="doi">10.1186/s13045-020-00924-z</pub-id><pub-id pub-id-type="pmid">32718354</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>TYT</given-names></name><name><surname>Simon</surname><given-names>LM</given-names></name><name><surname>Neill</surname><given-names>NJ</given-names></name><name><surname>Marcotte</surname><given-names>R</given-names></name><name><surname>Sayad</surname><given-names>A</given-names></name><name><surname>Bland</surname><given-names>CS</given-names></name><name><surname>Echeverria</surname><given-names>GV</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Kurley</surname><given-names>SJ</given-names></name><name><surname>Tyagi</surname><given-names>S</given-names></name><name><surname>Karlin</surname><given-names>KL</given-names></name><name><surname>Dominguez-Vidaña</surname><given-names>R</given-names></name><name><surname>Hartman</surname><given-names>JD</given-names></name><name><surname>Renwick</surname><given-names>A</given-names></name><name><surname>Scorsone</surname><given-names>K</given-names></name><name><surname>Bernardi</surname><given-names>RJ</given-names></name><name><surname>Skinner</surname><given-names>SO</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Orellana</surname><given-names>M</given-names></name><name><surname>Lagisetti</surname><given-names>C</given-names></name><name><surname>Golding</surname><given-names>I</given-names></name><name><surname>Jung</surname><given-names>SY</given-names></name><name><surname>Neilson</surname><given-names>JR</given-names></name><name><surname>Zhang</surname><given-names>XHF</given-names></name><name><surname>Cooper</surname><given-names>TA</given-names></name><name><surname>Webb</surname><given-names>TR</given-names></name><name><surname>Neel</surname><given-names>BG</given-names></name><name><surname>Shaw</surname><given-names>CA</given-names></name><name><surname>Westbrook</surname><given-names>TF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The spliceosome is a therapeutic vulnerability in MYC-driven cancer</article-title><source>Nature</source><volume>525</volume><fpage>384</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1038/nature14985</pub-id><pub-id pub-id-type="pmid">26331541</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Salit</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name><name><surname>Oliver</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Synthetic spike-in standards for RNA-seq experiments</article-title><source>Genome Research</source><volume>21</volume><fpage>1543</fpage><lpage>1551</lpage><pub-id pub-id-type="doi">10.1101/gr.121095.111</pub-id><pub-id pub-id-type="pmid">21816910</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Siegel</surname><given-names>PM</given-names></name><name><surname>Shu</surname><given-names>W</given-names></name><name><surname>Drobnjak</surname><given-names>M</given-names></name><name><surname>Kakonen</surname><given-names>SM</given-names></name><name><surname>Cordón-Cardo</surname><given-names>C</given-names></name><name><surname>Guise</surname><given-names>TA</given-names></name><name><surname>Massagué</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>A multigenic program mediating breast cancer metastasis to bone</article-title><source>Cancer Cell</source><volume>3</volume><fpage>537</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1016/s1535-6108(03)00132-6</pub-id><pub-id pub-id-type="pmid">12842083</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>JD</given-names></name><name><surname>Kahle</surname><given-names>KT</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Meerbrey</surname><given-names>KL</given-names></name><name><surname>Schlabach</surname><given-names>MR</given-names></name><name><surname>Schmitt</surname><given-names>EM</given-names></name><name><surname>Skinner</surname><given-names>SO</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>MZ</given-names></name><name><surname>Hartman</surname><given-names>ZC</given-names></name><name><surname>Rao</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Dominguez-Vidana</surname><given-names>R</given-names></name><name><surname>Liang</surname><given-names>AC</given-names></name><name><surname>Solimini</surname><given-names>NL</given-names></name><name><surname>Bernardi</surname><given-names>RJ</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Hsu</surname><given-names>T</given-names></name><name><surname>Golding</surname><given-names>I</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Osborne</surname><given-names>CK</given-names></name><name><surname>Creighton</surname><given-names>CJ</given-names></name><name><surname>Hilsenbeck</surname><given-names>SG</given-names></name><name><surname>Schiff</surname><given-names>R</given-names></name><name><surname>Shaw</surname><given-names>CA</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name><name><surname>Westbrook</surname><given-names>TF</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A sumoylation-dependent transcriptional subprogram is required for myc-driven tumorigenesis</article-title><source>Science</source><volume>335</volume><fpage>348</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1126/science.1212728</pub-id><pub-id pub-id-type="pmid">22157079</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>SS</given-names></name><name><surname>Griffin</surname><given-names>JN</given-names></name><name><surname>Date</surname><given-names>PP</given-names></name><name><surname>Liem</surname><given-names>KF</given-names></name><name><surname>Khokha</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>WDR5 stabilizes actin architecture to promote multiciliated cell formation</article-title><source>Developmental Cell</source><volume>46</volume><fpage>595</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2018.08.009</pub-id><pub-id pub-id-type="pmid">30205038</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>NU</given-names></name><name><surname>Claus</surname><given-names>E</given-names></name><name><surname>Sohl</surname><given-names>J</given-names></name><name><surname>Razzak</surname><given-names>AR</given-names></name><name><surname>Arnaout</surname><given-names>A</given-names></name><name><surname>Winer</surname><given-names>EP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases</article-title><source>Cancer</source><volume>113</volume><fpage>2638</fpage><lpage>2645</lpage><pub-id pub-id-type="doi">10.1002/cncr.23930</pub-id><pub-id pub-id-type="pmid">18833576</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Topper</surname><given-names>MJ</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Jiao</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Vaz</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Rodgers</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Riemer</surname><given-names>JB</given-names></name><name><surname>Day</surname><given-names>CP</given-names></name><name><surname>Yen</surname><given-names>RWC</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Easwaran</surname><given-names>H</given-names></name><name><surname>Hulbert</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Juergens</surname><given-names>RA</given-names></name><name><surname>Yang</surname><given-names>SC</given-names></name><name><surname>Battafarano</surname><given-names>RJ</given-names></name><name><surname>Bush</surname><given-names>EL</given-names></name><name><surname>Broderick</surname><given-names>SR</given-names></name><name><surname>Cattaneo</surname><given-names>SM</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>Rudin</surname><given-names>CM</given-names></name><name><surname>Wrangle</surname><given-names>J</given-names></name><name><surname>Mei</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>KKH</given-names></name><name><surname>Forde</surname><given-names>PM</given-names></name><name><surname>Margolick</surname><given-names>JB</given-names></name><name><surname>Nelkin</surname><given-names>BD</given-names></name><name><surname>Zahnow</surname><given-names>CA</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Housseau</surname><given-names>F</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Brock</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Epigenetic therapy inhibits metastases by disrupting premetastatic niches</article-title><source>Nature</source><volume>579</volume><fpage>284</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2054-x</pub-id><pub-id pub-id-type="pmid">32103175</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyons</surname><given-names>TG</given-names></name><name><surname>Traina</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Emerging novel therapeutics in triple-negative breast cancer</article-title><source>Advances in Experimental Medicine and Biology</source><volume>1152</volume><fpage>377</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-20301-6_20</pub-id><pub-id pub-id-type="pmid">31456195</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meerbrey</surname><given-names>KL</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Kessler</surname><given-names>JD</given-names></name><name><surname>Roarty</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>MZ</given-names></name><name><surname>Fang</surname><given-names>JE</given-names></name><name><surname>Herschkowitz</surname><given-names>JI</given-names></name><name><surname>Burrows</surname><given-names>AE</given-names></name><name><surname>Ciccia</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Schmitt</surname><given-names>EM</given-names></name><name><surname>Bernardi</surname><given-names>RJ</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Bland</surname><given-names>CS</given-names></name><name><surname>Cooper</surname><given-names>TA</given-names></name><name><surname>Schiff</surname><given-names>R</given-names></name><name><surname>Rosen</surname><given-names>JM</given-names></name><name><surname>Westbrook</surname><given-names>TF</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The pinducer lentiviral toolkit for inducible RNA interference in vitro and in vivo</article-title><source>PNAS</source><volume>108</volume><fpage>3665</fpage><lpage>3670</lpage><pub-id pub-id-type="doi">10.1073/pnas.1019736108</pub-id><pub-id pub-id-type="pmid">21307310</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minn</surname><given-names>AJ</given-names></name><name><surname>Gupta</surname><given-names>GP</given-names></name><name><surname>Siegel</surname><given-names>PM</given-names></name><name><surname>Bos</surname><given-names>PD</given-names></name><name><surname>Shu</surname><given-names>W</given-names></name><name><surname>Giri</surname><given-names>DD</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Olshen</surname><given-names>AB</given-names></name><name><surname>Gerald</surname><given-names>WL</given-names></name><name><surname>Massagué</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Genes that mediate breast cancer metastasis to lung</article-title><source>Nature</source><volume>436</volume><fpage>518</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1038/nature03799</pub-id><pub-id pub-id-type="pmid">16049480</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>E</given-names></name><name><surname>Mark</surname><given-names>KG</given-names></name><name><surname>Mocciaro</surname><given-names>A</given-names></name><name><surname>Watson</surname><given-names>ER</given-names></name><name><surname>Prabu</surname><given-names>JR</given-names></name><name><surname>Cha</surname><given-names>DD</given-names></name><name><surname>Kampmann</surname><given-names>M</given-names></name><name><surname>Gamarra</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>CY</given-names></name><name><surname>Rape</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Gene expression and cell identity controlled by anaphase-promoting complex</article-title><source>Nature</source><volume>579</volume><fpage>136</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2034-1</pub-id><pub-id pub-id-type="pmid">32076268</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otahal</surname><given-names>A</given-names></name><name><surname>Aydemir</surname><given-names>D</given-names></name><name><surname>Tomasich</surname><given-names>E</given-names></name><name><surname>Minichsdorfer</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>959</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-57707-2</pub-id><pub-id pub-id-type="pmid">31969600</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paiva</surname><given-names>SL</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Targeted protein degradation: elements of PROTAC design</article-title><source>Current Opinion in Chemical Biology</source><volume>50</volume><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2019.02.022</pub-id><pub-id pub-id-type="pmid">31004963</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Ayoub</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>YT</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Sha</surname><given-names>L</given-names></name><name><surname>An</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cianfrocco</surname><given-names>MA</given-names></name><name><surname>Su</surname><given-names>M</given-names></name><name><surname>Dou</surname><given-names>Y</given-names></name><name><surname>Cho</surname><given-names>US</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cryo-EM structure of the human MLL1 core complex bound to the nucleosome</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>5540</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-13550-2</pub-id><pub-id pub-id-type="pmid">31804488</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Vought</surname><given-names>VE</given-names></name><name><surname>Dharmarajan</surname><given-names>V</given-names></name><name><surname>Cosgrove</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A conserved arginine-containing motif crucial for the assembly and enzymatic activity of the mixed lineage leukemia protein-1 core complex</article-title><source>The Journal of Biological Chemistry</source><volume>283</volume><fpage>32162</fpage><lpage>32175</lpage><pub-id pub-id-type="doi">10.1074/jbc.M806317200</pub-id><pub-id pub-id-type="pmid">18829457</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punzi</surname><given-names>S</given-names></name><name><surname>Balestrieri</surname><given-names>C</given-names></name><name><surname>D’Alesio</surname><given-names>C</given-names></name><name><surname>Bossi</surname><given-names>D</given-names></name><name><surname>Dellino</surname><given-names>GI</given-names></name><name><surname>Gatti</surname><given-names>E</given-names></name><name><surname>Pruneri</surname><given-names>G</given-names></name><name><surname>Criscitiello</surname><given-names>C</given-names></name><name><surname>Lovati</surname><given-names>G</given-names></name><name><surname>Meliksetyan</surname><given-names>M</given-names></name><name><surname>Carugo</surname><given-names>A</given-names></name><name><surname>Curigliano</surname><given-names>G</given-names></name><name><surname>Natoli</surname><given-names>G</given-names></name><name><surname>Pelicci</surname><given-names>PG</given-names></name><name><surname>Lanfrancone</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells</article-title><source>Breast Cancer Research</source><volume>21</volume><elocation-id>123</elocation-id><pub-id pub-id-type="doi">10.1186/s13058-019-1216-y</pub-id><pub-id pub-id-type="pmid">31752957</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raja</surname><given-names>SJ</given-names></name><name><surname>Charapitsa</surname><given-names>I</given-names></name><name><surname>Conrad</surname><given-names>T</given-names></name><name><surname>Vaquerizas</surname><given-names>JM</given-names></name><name><surname>Gebhardt</surname><given-names>P</given-names></name><name><surname>Holz</surname><given-names>H</given-names></name><name><surname>Kadlec</surname><given-names>J</given-names></name><name><surname>Fraterman</surname><given-names>S</given-names></name><name><surname>Luscombe</surname><given-names>NM</given-names></name><name><surname>Akhtar</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The nonspecific lethal complex is a transcriptional regulator in <italic>Drosophila</italic></article-title><source>Molecular Cell</source><volume>38</volume><fpage>827</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.05.021</pub-id><pub-id pub-id-type="pmid">20620954</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rozengurt</surname><given-names>E</given-names></name><name><surname>Soares</surname><given-names>HP</given-names></name><name><surname>Sinnet-Smith</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Suppression of feedback loops mediated by PI3K/mtor induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance</article-title><source>Molecular Cancer Therapeutics</source><volume>13</volume><fpage>2477</fpage><lpage>2488</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-14-0330</pub-id><pub-id pub-id-type="pmid">25323681</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruthenburg</surname><given-names>AJ</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name><name><surname>Wysocka</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark</article-title><source>Molecular Cell</source><volume>25</volume><fpage>15</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2006.12.014</pub-id><pub-id pub-id-type="pmid">17218268</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>LR</given-names></name><name><surname>Foshage</surname><given-names>AM</given-names></name><name><surname>Weissmiller</surname><given-names>AM</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>The MYC–WDR5 nexus and cancer</article-title><source>Cancer Research</source><volume>75</volume><fpage>4012</fpage><lpage>4015</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-1216</pub-id><pub-id pub-id-type="pmid">26383167</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>LR</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Grieb</surname><given-names>BC</given-names></name><name><surname>Phan</surname><given-names>J</given-names></name><name><surname>Foshage</surname><given-names>AM</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Olejniczak</surname><given-names>ET</given-names></name><name><surname>Clark</surname><given-names>T</given-names></name><name><surname>Dey</surname><given-names>S</given-names></name><name><surname>Lorey</surname><given-names>S</given-names></name><name><surname>Alicie</surname><given-names>B</given-names></name><name><surname>Howard</surname><given-names>GC</given-names></name><name><surname>Cawthon</surname><given-names>B</given-names></name><name><surname>Ess</surname><given-names>KC</given-names></name><name><surname>Eischen</surname><given-names>CM</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC</article-title><source>Molecular Cell</source><volume>58</volume><fpage>440</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.02.028</pub-id><pub-id pub-id-type="pmid">25818646</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Islami</surname><given-names>F</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Ward</surname><given-names>EM</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Global cancer in women: burden and trends</article-title><source>Cancer Epidemiology, Biomarkers &amp; Prevention</source><volume>26</volume><fpage>444</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-16-0858</pub-id><pub-id pub-id-type="pmid">28223433</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wysocka</surname><given-names>J</given-names></name><name><surname>Swigut</surname><given-names>T</given-names></name><name><surname>Milne</surname><given-names>TA</given-names></name><name><surname>Dou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Burlingame</surname><given-names>AL</given-names></name><name><surname>Roeder</surname><given-names>RG</given-names></name><name><surname>Brivanlou</surname><given-names>AH</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development</article-title><source>Cell</source><volume>121</volume><fpage>859</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.03.036</pub-id><pub-id pub-id-type="pmid">15960974</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Yue</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>You</surname><given-names>Y</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>B</given-names></name><name><surname>Qiang</surname><given-names>B</given-names></name><name><surname>Shu</surname><given-names>P</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>HCF-1 promotes cell cycle progression by regulating the expression of CDC42</article-title><source>Cell Death &amp; Disease</source><volume>11</volume><elocation-id>907</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-020-03094-5</pub-id><pub-id pub-id-type="pmid">33097698</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Kottur</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Tsai</surname><given-names>YH</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Parker</surname><given-names>J</given-names></name><name><surname>Herring</surname><given-names>L</given-names></name><name><surname>Kaniskan</surname><given-names>HÜ</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Aggarwal</surname><given-names>AK</given-names></name><name><surname>Wang</surname><given-names>GG</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models</article-title><source>Science Translational Medicine</source><volume>13</volume><elocation-id>eabj1578</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abj1578</pub-id><pub-id pub-id-type="pmid">34586829</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>JL</given-names></name><name><surname>Ji</surname><given-names>JW</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Yin</surname><given-names>QS</given-names></name><name><surname>Qiu</surname><given-names>QL</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>SZ</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>RS</given-names></name><name><surname>Cai</surname><given-names>YZ</given-names></name><name><surname>Wang</surname><given-names>XF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cytotoxicity enhancement in MDA-MB-231 cells by the combination treatment of tetrahydropalmatine and berberine derived from corydalis yanhusuo W. t. wang</article-title><source>Journal of Intercultural Ethnopharmacology</source><volume>3</volume><fpage>68</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.5455/jice.20140123040224</pub-id><pub-id pub-id-type="pmid">26401350</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MTOR inhibitors at a glance</article-title><source>Molecular and Cellular Pharmacology</source><volume>7</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">27134695</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling</article-title><source>Oncogenesis</source><volume>9</volume><elocation-id>33</elocation-id><pub-id pub-id-type="doi">10.1038/s41389-020-0218-z</pub-id><pub-id pub-id-type="pmid">32157097</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Tao</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>MTOR signaling pathway and MTOR inhibitors in cancer: progress and challenges</article-title><source>Cell &amp; Bioscience</source><volume>10</volume><elocation-id>31</elocation-id><pub-id pub-id-type="doi">10.1186/s13578-020-00396-1</pub-id><pub-id pub-id-type="pmid">32175074</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78163.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zwart</surname><given-names>Wilbert</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xqtf034</institution-id><institution>Netherlands Cancer Institute</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.03.30.486357" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.03.30.486357"/></front-stub><body><p>Using combined in vivo and in vitro screens, this study identifies WDR5 as important for tumour growth and lung metastasis in a triple negative breast cancer. WDR5 promotes global translation rates and enhanced ribosomal protein expression, and targeting of WDR5 in combination with MTOR inhibition effectively reduces tumour cell growth and metastasis. Novel therapeutic strategies for triple negative breast cancer are urgently needed, and this study elegantly provides a novel therapeutic strategy that may contribute to improved clinical management of this patient population.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78163.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zwart</surname><given-names>Wilbert</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xqtf034</institution-id><institution>Netherlands Cancer Institute</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Heery</surname><given-names>David</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ee9ar58</institution-id><institution>University of Nottingham</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.03.30.486357">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.03.30.486357v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Richard White as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Greg Wang (Reviewer #1) and David Heery (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) 1/OICR-9429 is believed to target the WDR5-KMT2 interaction; meanwhile, the structure function study shown in Figure 4 and the genetic study in Figure 5 showed that WDR5's activation effects on ribosomal protein (RP) genes are independent of KMT2. These data almost indicate that OICR-9429 might affect WBM mediated WDR5 interaction to partners such as MYC, maybe via allosteric effect? Please explain these findings and expand the possible implications of these results more.</p><p>2) Initially it was stated that the focussed library covers 100 targets, but later it is stated that 7 minipools were used to cover the 69 targets in both screens? A list of the non-discovery target screened might also be useful in supplementary data, e.g. did these include other components of KMT2 or NSL complexes? please explain.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Overall, this study is well designed, comprehensive and well done. Also, the manuscript is generally well written and the data is well presented as well. The findings reported here in breast cancer can potentially be broadly applicable to many other cancers. The finding that the regulation of ribosome genes by WDR5 is independent of KMT2 is also novel. I would therefore support the publication at <italic>eLife</italic> after the below issues are addressed.</p><p>1/OICR-9429 is believed to target the WDR5-KMT2 interaction; meanwhile, the structure function study shown in Figure 4 and the genetic study in Figure 5 showed that WDR5's activation effects on ribosomal protein (RP) genes are independent of KMT2. These data almost indicate that OICR-9429 might affect WBM mediated WDR5 interaction to partners such as MYC, maybe via allosteric effect? Can author explain and expand a bit more?</p><p>2/ KMT2-WDR5 complex accounts for H3K4me1/2/3. And authors checked H3K4me3 in their functional studies in Figure 4-supplement. Would be better to test the H3K4me2 level in the ChIP-qPCR experiments.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Overall a very impressive and well-controlled study.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78163.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) 1/OICR-9429 is believed to target the WDR5-KMT2 interaction; meanwhile, the structure function study shown in Figure 4 and the genetic study in Figure 5 showed that WDR5's activation effects on ribosomal protein (RP) genes are independent of KMT2. These data almost indicate that OICR-9429 might affect WBM mediated WDR5 interaction to partners such as MYC, maybe via allosteric effect? Please explain these findings and expand the possible implications of these results more.</p></disp-quote><p>We appreciate the reviewers’ prediction and suggestion. We examined WDR5 binding to various interacting proteins when cells were treated with two “WDR5-KMT2” (WIN site) inhibitors: MM-401 or OICR-9429. This experiment shows that the interaction between WDR5 and c-Myc is indeed decreased by MM-401 and OICR-9429, likely via an allosteric effect (<xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>). Both inhibitors also disrupt RBBP5 or ASH2L interactions, albeit to a lesser extent (<xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>). Furthermore, it is reported that WIN site inhibitors C3 and C6 can displace WDR5 from the chromatin (Aho et al., 2019 Cell Rep PMID: 30865883 and Bryan et al. 2020 NAR, PMID: 31996893), consistent with our data that OCIR-9429 suppresses RP gene expression. However, C6 does not disrupt the binding between WDR5 and c-Myc or RBBP5 (Guarnaccia et al. 2021 Cell Rep, PMID: 33472061), suggesting that these different WIN site inhibitors exert different mechanisms of action. Therefore, we mention these possibilities as avenues for future studies with appropriate references in the revised Discussion.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>c-Myc and WDR5 interaction is disrupted by WDR5 inhibitors MM-401 or OICR9429.</title><p>(A) Western blot of M2-Flag or IgG control IP in Flag-WDR5-expressing LM2 cells after treatment with the indicated concentrations of MM-401. DMSO was used as treatment control. (B) Western blot of M2-Flag or IgG control IP in Flag-WDR5-expressing LM2 cells after treatment with inactive control compound OICR-0547 or the indicated concentrations of OICR-9429. DMSO was used as treatment control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78163-sa2-fig1-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>2) Initially it was stated that the focussed library covers 100 targets, but later it is stated that 7 minipools were used to cover the 69 targets in both screens? A list of the non-discovery target screened might also be useful in supplementary data, e.g. did these include other components of KMT2 or NSL complexes? please explain.</p></disp-quote><p>Thank you for pointing out the confusing description of the library that was assembled built and screened. Because some pINDUCER10 shRNA constructs did not efficiently knockdown our targets, we only screened part of the library that we initially assembled. We have now added the knockdown efficiency of shRNA in pGIPZ in the new Table S1 and indicated the shRNAs that have been used in in vitro and in vivo screens in Table S1. We have also added a new Table S2, which summarizes the results of the discovery and non-discovery targets in both in vivo and in vitro conditions. We have clarified the text to state the procedures more clearly and updated the numbers.</p><p>Of note, we were focused on screening for “druggable” epigenetic targets, and therefore we did not include additional components of the NSL complexes. Likewise, our library included only two other components of the KMT2 complex: SETD1A, which is a non-discovery target, and KMT2A, which is a depleted target. However, as we have described in the initial submission, knockdown of KMT2A with multiple shRNAs did not reproducibly affect in vitro colony formation and in vivo lung metastasis growth (Figure 5D-F)”.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Overall, this study is well designed, comprehensive and well done. Also, the manuscript is generally well written and the data is well presented as well. The findings reported here in breast cancer can potentially be broadly applicable to many other cancers. The finding that the regulation of ribosome genes by WDR5 is independent of KMT2 is also novel. I would therefore support the publication at eLife after the below issues are addressed.</p><p>1/OICR-9429 is believed to target the WDR5-KMT2 interaction; meanwhile, the structure function study shown in Figure 4 and the genetic study in Figure 5 showed that WDR5's activation effects on ribosomal protein (RP) genes are independent of KMT2. These data almost indicate that OICR-9429 might affect WBM mediated WDR5 interaction to partners such as MYC, maybe via allosteric effect? Can author explain and expand a bit more?</p></disp-quote><p>Please refer see our reply to comment (1) under “Essential Revisions” above.</p><disp-quote content-type="editor-comment"><p>2/ KMT2-WDR5 complex accounts for H3K4me1/2/3. And authors checked H3K4me3 in their functional studies in Figure 4-supplement. Would be better to test the H3K4me2 level in the ChIP-qPCR experiments.</p></disp-quote><p>We have not profiled H3K4me2 in that setting, which in our experience usually does not change as an intermediate histone mark. Our H3K4me3 results are consistent with a previous study (Aho et al., 2019 Cell Rep PMID: 30865883) that showed transcription changes caused by WIN inhibitors are not dependent on H3K4me3 alterations.</p></body></sub-article></article>